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ABSTRACT	  
 
 
 
Flaig, Stephanie Marge. M.S., Purdue University, December 2012. Development of 
Therapies to Treat Polycystic Kidney Disease. Major Professor: Bonnie Blazer-Yost. 
 
 
 
Polycystic kidney diseases (PKD) are genetic disorders characterized by fluid-
filled cysts in the kidney tubules and liver bile ducts.  There are two forms of PKD, 
autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive 
polycystic kidney disease (ARPKD).  The focus of the studies in this thesis has been on 
ADPKD.  The disease progresses slowly and the fluid-filled cysts grow in size due to 
increased rates of cell proliferation and fluid secretion into the cyst lumen.  The 
expanding cysts compromise the normal kidney function and result in a decrease of renal 
function to the point of end-stage renal failure in midlife. Cyst enlargement is due, at 
least in part, to chloride secretion via the cystic fibrosis transmembrane conductance 
regulator (CFTR) chloride channel.  Currently therapy is limited to renal cyst aspiration, 
dialysis, and eventually renal transplantation after organ failure, thus it has critical to 
determine possible drug therapies for the treatment of PKD. 
Previous studies showed that cyst fluid caused a secretory response in cells lining 
the cysts.  We hypothesized that once the cyst have expanded and become so large that 
they burst or leak, which could also occur due to renal injury or aging, the cyst fluid may 
stimulate additional cyst growth.  Lysophosphatidic Acid (LPA) was determined to be the 
active component of human cyst fluid, and we investigated the LPA stimulated signaling 
pathway. 
	   xi 
Our data suggest that the LPA stimulates chloride and fluid secretion by a 
combination of CFTR and Ca2+-Activated chloride channels (CaCC) and that the two 
channels may functionally be linked to each other.  The secretion is not occurring through 
a cAMP stimulated pathway, and it is possible that TMEM16A, a CaCC, plays a larger 
role than previously expected.  
Previous studies demonstrated that PPARγ agonists, insulin sensitizing drugs used 
to treat diabetes, inhibit chloride secretion by the collecting duct principal cells by 
decreasing CFTR synthesis.  It was logical therefore to considered PPARγ agonists as 
long-term treatment for PKD.  The first preclinical studied showed that high (20 mg/kg 
BW) dose pioglitazone, a PPARγ agonist, inhibited cyst growth in the PCK rat model, a 
slow progressing model, of PKD.  To continue to look at the effects of the PPARγ 
agonists another preclinical study was completed, which tested if there was a class action 
of PPARγ agonists and if a lower dose was effective in treating the cystic burden.  Using 
the PCK rat model, and another PPARγ agonist, rosiglitazone, a 24 week study was 
completed using 3 doses (4, 0.4, and 0.04 mg/kg BW).  4 mg/kg BW rosiglitazone is 
analogous to 20 mg/kg BW pioglitazone.  The data indicated that the rosiglitazone is 
effective in lowering the cystic burden, and importantly the low dose proved to be 
effective.  An additional rat model, the W-WPK rapidly progressing model was used to 
determine efficacy across multiple models, and to determine if there was a way to track 
the progress of the disease in a manner analogous to that used in human patients.  The 
animals were treated with pioglitazone using 2 doses (2 and 20 mg/kg BW), and were 
imaged using CT scans to track the progress of the disease.  The data suggest that 
pioglitazone was not as effective in the W-WPK rat model as it was the PCK rat model  
There was a trend however, that low dose PPARγ agonist was as effective as high dose.  
Even more important, the CT scans proved to be an effective way to track the progress of 
the disease in animal models.       
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CHAPTER 1. INTRODUCTION 
 
 
 
1.1   Polycystic Kidney Disease (PKD) 
Polycystic kidney disease (PKD) is a genetic disorder that is characterized by the 
accumulation and growth of fluid-filled cysts predominately in the kidney tubules and 
liver bile ducts.  It is normally diagnosed in adults with an incidence of 1:400 to 1:1000, 
making it one of the most common genetic diseases (5, 18, 42).  The disease progresses 
slowly and the fluid-filled cysts grow in size due to increased rates of proliferation and 
secretion.  The expanding cysts compromise the normal kidney function and result in a 
decrease of renal function to the point of end-stage renal failure in midlife (32).   
There are two forms of PKD, autosomal dominant polycystic kidney disease 
(ADPKD) and autosomal recessive polycystic kidney disease (ARPKD) (18).  ARPKD is 
rare and affects children, especially in the neonatal period.  It is characterized by tubular 
dilation in the kidneys (5, 18, 42).  ADPKD is the common form in the population and is 
characterized by the closed cysts that grow during a patient’s lifetime.  ADPKD is not 
specific to any race or gender (20), but there are gender dimorphisms in disease 
progression.  
ADPKD is caused by genetic mutations that occur on chromosomes 16 and 4.  In 
85% of the patients the genetic mutation occurs on chromosome 16, the PKD1 gene, 
which makes the protein polycystin 1.  The other 15% of genetic mutations occur on 
chromosome 4, the PKD 2 gene, which makes the protein polycystin 2 (4).  The proteins 
polycystin 1 and 2 are found on the primary cilia, and other locations throughout the cell.  
They either act as a transient receptor potential Ca2+ channel or they are proteins that 
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regulate the same class of Ca2+ channels (18, 32, 42, 43).  Mutations that affect Ca2+ 
levels in the cells will ultimately affect intracellular signaling pathways, such as ones that 
are involved in regulation of cAMP.  In the renal epithelial cells of the distal nephron and 
cortical collecting duct, Ca2+ influx inhibits the adenylyl cyclase/cAMP pathway. The 
lack of PKD 1 or PKD 2 in the primary cilia mechano-sensitive organelles in renal cysts, 
inhibits the Ca2+ influx.  Thus, increasing the activity of the adenylyl cyclase leading to 
an increase in intracellular cAMP.  It is further exacerbated by a decrease in an 
intracellular Ca2+-stimulated phosphodiesterase.  The increase in cAMP, has been widely 
documented as a common finding in cystic cells (5, 18).  With an increase in cAMP, 
there is an increase is protein kinase A (PKA), which thereby will alter intracellular 
signaling pathways that control ion flow as well as fluid secretion (18).   
It is speculated that patients are born with every cyst that will ever develop (13) 
and over time these cysts slowly expand and fill with fluid.  Surprisingly, this cyst 
expansion does not compromise renal function until later in life, but once the renal 
function declines is does so at a severe rate (5).  The symptoms of PKD that precede 
renal failure, include cyst formation in organs other than the kidney, aneurysms, flank 
pain, hematuria, renal colic, urinary tract infections, and hypertension (18).  The renal 
pathology is the primary cause for the deaths associated with PKD in both ADPKD and 
ARPKD.  The other most common area of concern besides renal pathology is the liver 
cysts that arise in the lining of the hepatic bile duct.  Currently therapy is limited to renal 
cyst aspiration, dialysis (currently approximately 4% of dialysis patients are due to PKD), 
and eventually renal transplantation after organ failure (20).  Thus, it is critical to look at 
possible therapies for the treatment of PKD.  
  
 
 
 
 
 
 
 
 
 
	   3 
1.2   Cyst Fluid/Lysophosphatidic Acid (LPA) and PKD Disease Progression 
The growth of individual cysts is determined to be combined rates of epithelial 
proliferation and fluid transport into the cyst cavity (14).  The fluid transport is 
secondary to aberrant ion secretion into the cyst lumen.  In renal cysts it has been 
observed that cAMP is increased resulting in over stimulation of ion channels (12).  By 
inhibitor and electrophysiology studies, it has been shown that the cystic fibrosis 
transmembrane conductance regulator (CFTR) is one of the major ion channels 
responsible for the increase of chloride secretion in both the kidney tubules and liver bile 
ducts (10, 24).  
It was shown that cyst fluid from human patients stimulate a secretory activity from 
normal renal epithelial cells and enhance cyst growth in vitro (12, 34, 54).  In Madin 
Darby Canine Kidney (MDCK) cells it was shown by Grantham et al., that the 
component of the human cyst fluid is lipid-like that stimulates the chloride secretion via 
CFTR (14).  In a subsequent paper, the group proposed that the lipid-like active 
component of cyst fluid was forskolin, but could not reveal the origin of this lipid-like 
plant compound (34).   
Our laboratory has extended the Grantham studies using electrophysiological 
techniques (46) to examine the effect of human cyst fluid when added to the mpkCCDcl4 
(mouse principal cells of the kidney cortical collection duct, clone 4) cell line (1).  It was 
found that human cyst fluid stimulated at least two chloride channels and that 
lysophosphatidic acid (LPA) is an active component in the human cyst fluid.  LPA, 
present in both cyst fluid and serum, stimulated a chloride secretory response (2) LPA, a 
small glycerophospholipid, plays a role in cell signaling pathways and is released into 
the interstitial space during renal injury. Under normal conditions, LPA does not interact 
with the basolateral receptors because it is attached to serum proteins or proteins such as 
albumin and gelsolin found in the cyst fluid (30, 40, 41).  Thus it is reasonable that an 
occurrence of renal injury to a PKD patient could release the cyst fluid or simply the cyst 
could burst, allowing the basolateral membrane to be in contact with LPA (39).  LPA 
could be potential target for therapy, but the intracellular pathway has to be elucidated in 
more detail.  For example there are at least five known G-protein- coupled receptors: 
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LPA1-LPA5 (9), and their general pathway has already been established (Figure 1) from 
the Choi, et al.  Yet, the intracellular signaling pathway for the activation of LPA from 
the cyst fluid remains uncharacterized.   
 
 
 
1.3   PPARγ agonists 
Peroxisome proliferator activator receptor gamma (PPARγ) agonists are insulin-
sensitizing agents and are commercially available for the treatment of type 2 diabetes 
mellitus (6, 8, 35, 52, 53).  PPARγ is expressed in the renal collecting duct (16).  The 
nephron controls the salt and water balance via the ion transport systems and in the 
collecting duct, sodium and water reabsorption are under hormonal control (31).   
At high concentrations, PPARγ agonist therapy causes fluid retention, initially the 
focus of PPARγ agonist induced fluid retention was on the epithelial sodium channel 
(ENaC) (7, 15, 19, 29, 38, 47, 56).  However inhibitor and electrophysiology studies in 
various principal cell types suggest that ENaC is not the target of the PPARγ agonists. 
Studies completed in cell culture models of the principal cell type of the distal nephron 
have shown the PPARγ agonists inhibit cAMP-stimulated anion transport by inhibiting 
the synthesis of the CFTR protein (28).  As noted above CFTR is the chloride channel 
responsible for the cyst growth in the kidney and liver cysts in PKD (10, 21, 24).  Thus, 
it is reasonable to hypothesize PPARγ agonists could be used as treatment for PKD.  
    
 
 
1.4   Current PKD Therapies 
Currently there are several drugs in clinical trials for the treatment of PKD.  There 
are three general areas that drugs are targeting; proliferative pathways, fluid and 
electrolyte transport pathways, and a combination of both.  One of the proliferative 
pathway targeting drugs, mTOR (rapamycin) inhibitors, blocks cell growth and 
proliferation.  The pre-clinical trials were conducted in the mouse models and the results 
were positive (33, 50).  However, in clinical trials the drug did not do as well as expected.  
Some of the patients left the trial due to the side effects associated with the drug and 
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efficacy did not match the preclinical assays (36, 48).  On a more positive outlook, the 
drugs that are targeting the fluid and electrolyte pathways are showing more promising 
data.  The vasopressin, V2 receptor antagonist, Tolvaptan has shown to be the most 
promising.  It works by inhibiting the adenylyl cyclase pathway, thus decreasing the 
amount of chloride secretion and it has progressed from animal models into phase III 
clinical trials (44, 45).    
 In consideration of therapies for the treatment of PKD, there are many factors that 
play key roles.  A drug that has adverse side effects that eventually will cause more 
damage than the disease itself would not be effective.  This is the reason the mTOR 
inhibitors have been abandoned.  To be beneficial, the drug needs to be at a higher dose, 
which is dangerous (33, 50).  ADPDK is a slowly progressing disease, thus the earlier the 
treatment the better, but this also means that a patient needs to remain consistently on a 
drug from the time of diagnosis.  Tolvaptan has an adverse effect on a patient’s lifestyle 
that makes the drug less pleasing to the patients.  The most serious side effect is the risk 
of dehydration due to the inability to concentrate urine.  There is also the issue of cost for 
a drug.  The more expensive the drug the less likely the patients will be able to afford it 
for a long period of time.  And the current cost of Tolvaptan is approximately $300,000 a 
year.  Ultimately it is clear that there needs to be other drugs that could be used in the 
treatment of PKD, that are less harmful and more patient friendly.   
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CHAPTER 2. MATERIALS AND METHODS 
 
 
 
2.1   Cell Culture 
The well-characterized mpkCCDcl4 renal cell line of mouse principle cells of the 
cortical collecting duct were grown at 37°C in a humidified incubator continuously 
gassed with 5% CO2.  The culture media consisted of DMEM/F12 base media 
supplemented with 2% fetal bovine serum (FBS), 0.4 M penicillin/streptomycin, 0.5 M 
glutamax, 3.1x10-8 M ciproflaxin, 6.37 x10-5 M transferrin, 1.16 x10-4 M selenium, and 
1.0 x10-9 M T3.  In some cases additional supplements were added to the media, such as 
1.57 x10-8 M epidermal growth factor, 4.1 x10-8 M dexmasome, and 0.0224 M glucose.  
Media was replaced every 2 to 3 days.  Cell cultures were maintained in plastic 75 cm2 
flasks until confluence.  At confluence, the cells were subcultured and reseeded into 
another 75 cm2 flask, and permeable supports in 6-well plates.  They were subcultured 
by first warming the media, 20 mL of Hanks Balanced Salt Solution (HBSS) and 2 mL 
trypsin with EDTA to 37°C.  The flask containing the confluent mpkCCDcl4 renal cell is 
taken out of the incubator and placed into the biosafety cabinet.  The old media is 
removed and 10mL of HBSS is added to the flask.  During this time, quickly the trypsin 
with EDTA is filtered and diluted with 8 mL of HBSS.  Then the HBSS is removed from 
the flask and the diluted trypsin is placed in the flask and then put back in the incubator 
for approximately 5 minutes.  As soon as the cells were released from the flask, 10mL of 
serum containing culture media is added to the flask to deactivate the trypsin.  The 
culture media with cells and diluted trypsin with HBSS is then placed into a 50 mL 
centrifuge tube and is placed into a centrifuge for 5 minutes at 1000 rpm.  The 
supernatant is removed, leaving behind a solid pellet of cells, which is then mixed with 
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10 mL of culture media.  From the resuspended cells, only a few drops are placed into a 
new flask already containing 10 mL of culture media.  Then 14 mL of culture media is 
added to the remaining cell pellet suspension.  1.5 mL of this solution is placed in each 
well of a transwell 6-well plate and 2 mL of media on the bottom.  The plates are 
cultured for 13-16 days in order to form high resistant monolayers.   
 
 
2.2   Electrophysiology 
After approximately 14 days of growth on the transwells the cells formed a 
confluent monolayer.  At this time the permeable membrane was excised, mounted into 
Ussing chambers and clamped into electrophysiology set-ups. The cells were bathed in 
serum-free media, which contained only DMEM/F12, sodium bicarbonate, 
penicillin/streptomyocin, and glutamax.  They were maintained at 37°C via a water jacket 
buffer reservoir that was continuously gassed with 95% 02/5% CO2.  The trans-epithelial 
potential difference (PD) was measured and clamped to zero leaving the resulting short-
circuit current (SCC) which is a measure of net ion flow.  A positive change in SCC is 
defined as an anion moving in a secretory direction (basolateral to apical) or a cation 
moving in an absorptive direction (basolateral to apical).  During the experiments the 
trans-epithelial PD was switched from 0 to 2 mV every 200 seconds, thus using Ohm’s 
law the trans-epithelial resistance (TEER) was calculated from the resulting current 
change.  Cultures with resistances lower than 1000 Ω /cm2 were discarded.  For each 
experiment, the inhibitor, enhancer, or hormone was added to either the basolaterol or 
apical side of the cells depending on where their presence was effective.  
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2.3   Immunohistochemistry 
 After approximately 14 days of growth on the permeable supports, the cells were 
fixed and stained for zonula occuldens protein 1 (ZO1), a tight junction protein, and 
TMEM16A, a Ca2+-activated chloride channel.  Permeable supports containing confluent 
monolayers were washed twice with cold 1% phosphate buffer saline (PBS) for 10 
minutes for each wash.  After which 1mL of 3.7% paraformaldehyde in PBS was added 
to the cells for 5 minutes.  The cells were then washed twice with cold 1% PBS for 10 
minutes each.  The cells were permeabilized with 0.25% NP-40 in PBS for 15 minutes.  
Again, the cells were washed twice with cold 1% PBS for 10 minutes each.  The primary 
antibody was made up to a 1:50 dilution in 1% PBS with 10% fat-free dry milk.  The 
primary antibody was added to the permeable supports and allow to incubate overnight 
at 4°C while gently being swirled on a plate shaker.  After overnight incubation the cells 
were washed three times with cold 1% PBS for 5 minute each.  The secondary antibody 
was made up to a 1:200 dilution in 1% PBS with 10% fat-free dry milk.  The secondary 
antibody was added to the wells and the plate incubated at 37°C for 30 minutes.  After 
30 minutes the wells were washed three times with cold 1%PBS while avoiding light 
exposure.  The permeable supports were mounted face up onto microscope slides to be 
viewed on the fluorescent microscope.  
 
 
 
2.4   cAMP assay 
 Cells cultured on permeable supports for 14 days were used for analysis of 
intraceullar cAMP (Direct cAMP EIA kit purchased from Enzo Life Sciences).  The 
cells were stimulated with LPA, forskolin, antidiuretic hormone (ADH), or diluent for 20 
seconds, 1 minute, or 5 minutes.  For stimulation, the effectors were added to the 
basolateral side of the cells and the plate was gently swirled.  After which, 1 mL of lysis 
buffer (1% Triton X-100 in 0.1 M HCl), was added to the well and the plate was placed 
in the incubator for 10 minutes.  The plate was taken out of incubator and the cells were 
rubbed off by rotating a rubber policeman on the transwell 30 times, alternating direction 
ever 5 times.  The media, cells, and lysis buffer were removed and collected.  The 
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collected fluid was centrifuge on high speed for 2 minutes.  The standards were made by 
using the stock 2,000 pmol/mL warmed to room temperature.  Five standards were made 
by serial dilutions in 0.1M HCl, to produce 200 pmol/mL, 50 pmol/mL, 12.5 pmol/mL, 
3.13 pmol/mL, and 0.78 pmol/mL.  Wash buffer was prepared by diluting 5mL of the 
supplied concentrated wash buffer with 95 mL of deionized water.  The 96-well plate to 
be used to analyze the samples was a goat anti-Rabbit IgG microtiter plate.  Initially 50 
µL of neutralizing reagents was added into each well except the total activity (TA) and 
blank well.  Then 100 µL of the 0.1 M HCl was added into the non-specific (NSB) and 
the Bo (0 pmol/mL standard) wells.  Another 50 µL of 0.1 M HCl was added to the NSB 
well.  Then for the correct corresponding wells, 100 µL of each of the 5 standards was 
pipetted into their appropriate labeled well.  Next, 100 µL of the supernatant of the 
centrifuge samples was added to the appropriate wells.  Then, 50 µL of the cAMP direct 
conjugate was added to each well except the TA and blank wells, and 50 µL of the 
antibody was added into each well except the blank, TA, and NSB well.  The plate was 
sealed and covered with parafilm and aluminum foil and incubated for 2 hours on a plate 
shaker at approximately 500 rpm at room temperature.  After the 2 hour incubation 
period the contents of the wells was removed by using a glass pipette and a vacuum.  
Each well was washed with the diluted wash buffer by added 400 µL to each well.  This 
washing procedure was repeated 2 times, after the final wash was completed the plate 
was gently tapped onto lint free paper towel to make sure to remove any of the wash 
buffer.  At this point 5 µL of the cAMP direct conjugate was added to the TA well, and 
200 µL of substrate solution was added into each well.  The plate was then sealed again 
and incubated at room temperature for one hour without shaking.  After the one hour 
incubation, stop solution was added into every well.  Once the stop solution was added 
the plate then could placed into the plate reader and the optical density was read at 405 
nm.  After which, a standard curve could be generated by graphing the standard 
concentration vs. the mean optical density on a log scale.   
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2.5   Fluid Secretion 
 A fluid secretion protocol was modified from Neufeld, et.al. (27).  After 
approximately 14 days of growth on the permeable supports, the mpkCCDcl4 renal cells 
have grown to confluence.  At this time, the 6-well plates, containing the permeable 
supports were removed from the incubator and placed into a biosafety cabinet.  As the 
cells grow on the supports, the basolaterol side of the cells is facing the permeable 
supports, and the apical is facing the upper media.  0.114 mM LPA or diluent were 
added to the basolateral side of the transwell.  Every 30 second time point the transwells 
were either stimulated with diluent or with LPA.  During stimulation the plate was 
gently swirled.  After 5 minutes of stimulation the media was removed using a P1000 
pipetteman and placed into a pre-weighed microcentrifuge tube.  The tubes were then re-
weighed, and the weights were compared to the microcentrifuge tube without the 
collected media.  The difference was taken to determine exactly how much fluid was in 
the tube, and it was determined that every µg would be a µL of fluid.  There were two 
protocols: 1) the cells were stimulated for 24 hours; 2) the media was left on top and 
then stimulated.  In the 24 hour fluid secretion protocol, the cells were stimulated the day 
before and 500 µL of autoclaved oil was placed on the top of the well to help reduce the 
lost of fluid due to evaporation.  The media and oil was removed and placed into a 
microcentrifuge, and centrifuge to separate the oil from the fluid.  The oil was removed 
and the microcentrifuge tube was weighed and compared to the unweighed tube.  In the 
fluid secretion protocol in which the media was left on top before stimulation with LPA, 
the wells were stimulated and after 5 minutes the media was removed and placed in a 
pre-measured microcentrifuge tube and compared to its original mass.  
 
 
 
2.6   Animals 
The PCK rats were purchased from Charles River Laboratories, Inc. (Wilmington, 
MA) and a breeding colony maintained at Indiana University School of Medicine 
(IUSM).  The PCK rat model was chosen for its orthologous genetic mutation to ARPKD 
and the presence of many the phenotypic characteristics of human ADPKD.  The Pck 
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gene of the rat is an orthologue to the PKHD-1 gene responsible for ARPKD (49).  The 
animal model develops both kidney and liver fibrocystic diseases, and is slow 
progressing.  There is also a gender dimorphism of the rat model; females develop more 
severe liver disease while males develop more severe kidney disease, which resembles 
what is seen in human ADPKD (22).	  	  	  
The W-WPK rat colony was already established at IUSM.  The W-WPK rat 
model is a rapidly progressing model, that has full development of terminal disease at the 
age of 21 days (11).  The mutant gene is the MKS3 gene in humans and Mks3 gene in 
rats.  The protein associated with the gene mutation is called Meckelin, which has 995 
amino acids in humans and 997 amino acids in the rat and they are 84% identical and 
91% similar (37).  The W-WPK rat was developed for its renal cystic disease, but it has 
demonstrated phenotypic CNS malformations, such as hypoplasia, agenesis of the corpus 
callosum, and severe hydrocephalus.  As such, it proved to be a good model for both 
renal cystic disease and Meckel-Gruber Syndrome (11).	  	  	  
Institutional Animal Care and Use Committees approved all protocol procedures 
for both animal models.  Animals were monitored and each day with the help of the 
laboratory animal resource center (LARC).  
 
 
 
2.7   Study Design and Protocols 
 
 
 
2.7.1   Rosiglitazone 
Rosiglitazone (Avandia®) are purchased in tablet form.  After weaning, at four 
weeks of age, the PCK rats were randomly separated out into groups.  Only females 
were used due to their development of more sever liver disease.  There were three 
treatment groups, and one control group.  All animals were kept in the same room, with 
the same type of bedding, and water.  Control animals were fed a diet of Purina no. 5002 
LabDiet.  The treatment groups were fed Purina no. 5002 LabDiet supplemented with 
rosiglitazone calculated to provide 4 mg/kg body weight (BW), 0.4 mg/kg BW, and 0.04 
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mg/kg BW daily.  The concentrations were dependent on the estimated animal 
consumption of their base diets.  The rats were kept on control or supplemented diet for 
24 weeks, throughout the study various parameters were recorded.  At 8 weeks a 24-hour 
urine sample was collected and glucose levels were measured.  A hematocrit was 
measured to assess possible fluid retention.  The day before they were 24 weeks old, the 
animals were placed in metabolic chambers to collect urine to later be centrifuge and 
collected and analyzed.  At week 24, the animals were anesthetized with 100 mg/kg 
intraperitoneally injected sodium pentobarbital.  After the animals no longer had tail, 
foot, and eye reflexes the sacrifice was begun.  Blood was collected via intracardiac 
puncture for serum analysis.  Body weight was measured and a laparotomy was 
performed.  Urine protein was assessed using an uristix, then the left kidney and right 
liver lobe was removed, weighed, and frozen in liquid nitrogen.  The body was then 
flushed with a saline solution through a catheter in the left ventricle followed by 4% 
paraformaldehyde in phosphate buffer to perfusion fix the animal.  The right kidney, the 
left liver lobe, and heart were removed, weighed and kept in 4% paraformaldehyde.  The 
kidney and liver were to be later used for histological analysis.      
 
 
2.7.2   Pioglitazone 
Pioglitazone (Actos®) was purchased as 15 mg tablets.  The drug was made up in 
grape juice to enhance palatability.  Animals received either 20 mg/kg BW or 2.0 mg/kg 
BW.  It was fed to the animals by daily weighing the animals and feeding them the graph 
juice supplemented with Pioglitazone at 1 µL per gram of body weight.  The W-WPK rat 
model was used and treatment was started on day 5, because of the rapid progression.  
On day 5 the entire litter was started due to the fact that is was difficult at this age to 
determine which ones were cystic or normal.  On day 5, they were weighed and received 
grape juice either supplemented with drug or nothing.  A tail clip was performed and 
blood glucose was determined and blood was collected for hematocrit.  The animals 
continued to stay on the treatment either till day 10 or day 18.  For everyday of 
treatment, the animals were weighed and treated with either grape juice or grape juice 
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supplemented with pioglitazone.  They were treated by using a pipetteman and received 
1 µL per gram of BW.  The animals were sacrificed on day 10 or day 18 of treatment.  
Some were randomly chosen to be scanned for CT images.  The animals were initially 
anesthetized with 100 µg/g intraperitoneally injected sodium pentobarbital.  After the 
animals no longer had tail, foot, and eye reflexes the sacrifice begun.  Body weights 
were determined, urine if present was collected directly from their bladder, and blood 
was collected for serum analysis, hematocrit and blood glucose levels.  A kidney was 
removed, weighed, and frozen in liquid nitrogen.  The body was then flushed with a 
saline solution, followed by 4% paraformaldehyde in phosphate buffer to perfusion fix 
the animal.  The other kidney, liver, heart, and head were collected and kept in 4% 
paraformaldehyde.  The kidney and head were to later to be used for histological 
analysis. 
 
 
 
2.8   Histological Analyses 
Slides were prepared at the histology center in the Anatomy and Cell Biology 
Department, IUSM.  In the rosiglitazone study, the liver and the kidney were embedded 
in paraffin, transversely sectioned and stained with hematoxylin, and eosin as well as 
with picrosiruis red for fibrosis analysis.  In the pioglitazone study the kidney and head 
sections were embedded in paraffin.  The kidney was sectioned transversely and either 
unstained or stained with hematoxylin, and eosin.  The head was coronally sectioned and 
either unstained or stained with hematoxylin, and eosin.  The kidneys for both studies 
were analyzed by completing point count stereology.  Point count stereology is when a 
grid is placed on top the image of the kidney and then for every point of intersection it 
was either counted as a point for tissue or one for cyst.  This provides a numerical value 
to the tissue and the cyst, so the renal cyst percentage could be calculated.  The liver for 
the rosiglitazone study was analyzed in a similar manner, except that the pictures of the 
livers were from the picrosiruis red staining, which also stains for the fibrosis.  At every 
point of intersection, it was either counted as a point for tissue or one for cyst and 
fibrosis, thus the percent fibrocystic could be determined.  Finally, the brains for the 
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pioglitazone study were analyzed by using ImageJ (NIH), in which the outline of the 
ventricles was drawn and the program was able to calculate the perimeter and the area in 
square centimeters.  
 
 
 
2.9   CT Imaging 
 In the pioglitazone study, the W-WPK rats were imaged at two time points, 10 
days and 18 days.  The rats were taken from the rest of the litter and moved to the CT 
imaging facility in the IU Health Hospital to be scanned on the Siemens Biograph 
Truepoint PET•CT.  Before the imaging could begin the rats were slightly anesthetized 
by injecting them with 70% diluted sodium pentobarbital and where kept warm by 
placing them under a heating lamp.  Once the rat was no longer moving a contrasting 
fluid was injected into the tail vein, and then the rat was imaged approximately 10 times 
by the scanner.    
 
 
 
2.10   CT Analysis 
 The CT scans were copied on to disks and analyzed using the Philips Extended 
BrillianceTM Workspace (V2.0.1).  Each animal’s data was uploaded to the program and 
the best series of images was determined.  The CT value range was determined for the 
functioning renal tissue and for the cyst tissue.  The CT ranges were different between the 
10 day animals compared to the 18 day animals.  The CT ranges were applied to each 
animal analysis, which then a 3-dimensional kidney was built slice by slice for both the 
normal renal tissue and the cystic tissue per animal.  The program calculated the volume 
of the 3-dimensional image in cubic millimeters and thus the renal cyst volume 
percentage could be calculated by comparing the normal renal tissue volume with the 
cyst tissue volume. 
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2.11   Statistical Analysis 
 Comparisons between data groups were performed using a Student’s t-test for 
unpaired samples.  Where indicated further statistical analysis was performed using 
Anova one-tailed probability test.  P value less than 0.05 were used to denote statistical 
significance.  Statistics were completed using the ProStat (version 5.5). 
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CHAPTER 3. RESULTS 
 
 
 
3.1   Electrophysiology 
The laboratory was investigating the active component of human cyst fluid, 
lysophosphaditic acid (LPA), to determine the pathway controlling cyst expansion.  For 
all studies the well characterized mpkCCDcl4 (mouse principal cells of the kidney cortical 
collection duct, clone 4) cell line (1) were used.  Previously the laboratory showed that 
cyst fluid (10% v/v) was more effective in stimulating ion transport when added on the 
basolateral side (Figure 2). The response had several secretory components (2).  Since 
the laboratory already has shown the LPA was the active component of cyst fluid in 
previous experiments (2) it was logical to test the response after the addition of LPA to 
the basolateral side of the cells (Figure 3).  The same response was shown in comparison 
to the addition of cyst fluid, in which there was a strong initial ion transport and then a 
smaller secondary ion transport.   
The laboratory showed the cyst fluid response was not due to sodium absorption, 
but chloride secretion (2), thus the next step was to look at the identity of the chloride 
channels.  The cells were pretreated with two chloride inhibitors, GlyH-101 and tannic 
acid, then stimulated with cyst fluid.  GlyH-101 is a specific inhibitor of the CFTR 
chloride channel, and tannic acid is an inhibitor of Ca2+-activated chloride channels 
(CaCC), including the recently described TMEM16A (Figure 4).  GlyH-101 inhibited 
majority of the secretory response, and tannic acid partially inhibited the chloride 
transport.  The laboratory also previously completed an experiment in which different 
concentrations of LPA were added to determine the maximal concentration that 
mimicked the addition of human cyst fluid (10% v/v).  It was determined that the LPA 
	   17 
concentration of 0.05 to 50 mM maximally stimulated the mpkCCDcl4 cells (2).  Having 
established LPA as the active component of cyst fluid the next step was to look the 
chloride channels in response to the basolateral addition of LPA.  The cells were 
pretreated with GlyH-101 and tannic acid prior to the addition of LPA (Figure 5).  The 
results were similar to the effects in the human cyst fluid experiment.  If one envisions 
the chloride secretory response as composed of two overlapping ion secretory transports, 
GlyH-101 partially inhibited the first secretory response completely and inhibited the 
second response, while tannic acid inhibited the second ion transport, but affected the 
first ion transport slightly.   
To further investigate the cyst fluid response, it was critical to determine if cyst 
fluid from multiple sources elicited the same response when added to the basolateral side 
of the cells.  Cyst fluid from different patients was added to the basolateral side of the 
cells (Figure 6).  There was a substantial variability in the responses tested, and it was 
determined that cyst fluid 12 (CF-12) would be used in later experiments.   
Antidiuretic hormone (vasopressin) stimulates CFTR through the cAMP pathway.  
Thus a comparison of basolateral addition of LPA and ADH was completed (Figure 7).  
Antidiuretic hormone seems to be a more abrupt and intense ion transport.   
Fetal bovine serum (FBS) contains enough LPA to maximally stimulate the 
chloride channels (2).  It was important to look at the chloride channels, thus the cells 
were pretreated with the chloride channel inhibitors, GlyH-101 and tannic acid and added 
together (Figure 8).  GlyH-101 partially inhibits the first secretory response and inhibits 
second secretory response, and tannic acid slightly inhibits the first secretory response 
and completely inhibits the second.  
It was important to classify the LPA receptor responsible for the chloride 
secretory response.  There are at least five known G-protein- coupled receptors for LPA: 
LPA1-LPA5 (9).  Initially, LPA receptor 5 was investigated.  This was done by comparing 
the ion transport the responses to ester LPA and ether LPA.  Ether LPA is known to 
preferentially stimulate LPA receptor 5.  A comparison of stimulatory effects of eqimolar 
amounts of ether and ester LPA indicated that ester LPA had a much greater stimulatory 
effect than ether LPA suggesting LPA receptor 5 was not involved (Figure 9).    
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Other, LPA receptors of interest, where LPA receptor 1 and 3.  The cells were 
pretreated with LPA 1/3 receptor antagonists, Ki16425 and VPC51299 supplied by 
Professor Kevin Lynch, to the basolateral side then there was an addition of ester LPA to 
the basolateral side (Figure 10).  The out come of the experiments indicated that neither 
LPA receptor 1 or 3 was contributing to the secretory response.    	   To further characterize the ion secretory response to LPA stimulation, we studied 
two compounds that alter intracelluar Ca2+ in the cells.  Ionomycin, which increases 
intracellular Ca2+ by forming channels that allow Ca2+ influx from the extracellular 
medium and Bapta-AM, which chelates intracellular Ca2+.  One would expect the 
ionomyocin would potentiate the Ca2+-activated chloride channels (CaCC), and that 
Bapta-AM would inhibit the same channel. 
 Ionomyocin caused an initial transport event, then with the addition of LPA, the 
normal secretory response was decreased, which was unexpected.  Since ionomyocin 
increases intracellular Ca2+ stores, thus if chloride is secreted by CaCC, it is expected that 
the transport events associated with basolateral addition of LPA would increase, which 
was not the case.  Bapta-AM as expected when added to the renal cell line the chloride 
secretory response to LPA was diminished (Figure 11).  Bapta-AM chelates the Ca2+ 
stores, thus if the LPA secretory response it due, in partial, to CaCC, if there is no Ca2+ 
present, then the secretory event would be expected to be dimished.  The next step was to 
preincubate with ionomyocin and Bapta-AM before the addition of human cyst fluid 
(Figure 12), to see if it reacted in the same way as the LPA did, since the laboratory has 
already showed the LPA is the active component of cyst fluid.  The results showed a 
similar response as seen with LPA, the ionomyocin decreased the secretory event, again 
unexpectedly, and Bapta-AM dimished the response as expected. 
Although the situation is complex, the Ca2+ is involved and the identity of the 
CaCC remains unknown.  Previous inhibitor experiments suggested that it might be 
TMEM16A.  And several references indicated there are more specific inhibitors for 
TMEM16A.  This was investigated by using two different TMEM16A inhibitors, besides 
the original tannic acid, namely T16Ainh-A01 and digalliac acid (25).  The cells were 
pre-treated with T16Ainh-A01 inhibitor and then human cyst fluid was added  
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(Figure 13).  Which, unexpectedly the inhibitor did not have an effect on the chloride 
secretory response.  Also, the cells were pretreated with digalliac acid and then FBS was 
added to the basolateral side (Figure 14), similar to the T16Ainh-A01, the inhibitor did 
not have an effect on the chloride secretory response. 
 
 
 
3.2   Immunohistochemistry 
 By the electrophysiology data, it is clear that there are potentially two channels in 
which chloride secretion occurs, CFTR and TMEM16A.  It has already been established 
the renal cells have small amounts of CFTR (10, 24), but the presence of TMEM16A is 
unknown.  Thus using immunohistochemistry, the TMEM16A channel could be stained.  
After approximately 14 days of growth, the staining protocol was tested on the 
mpkCCDcl4 renal cell line by staining for ZO1, a tight junction protein, that is present in 
every epithelial cell.  The cells were stained properly and the protocol worked.  The next 
step, completed by Dr. Criss Hartzell, was to use a primary antibody that attaches to the 
TMEM16A protein, and using the secondary antibody, fluorescein isothiocyanate 
(FITC) to determine if TMEM16A is present in the renal cell line while viewing the cells 
using a confocal microscopy (Figure 15). 
 
 
 
3.3   cAMP 
 A cAMP assay was completed to further investigate the LPA stimulatory 
pathway.  The only receptor that activates cAMP production is LPA receptor 4, thus 
determining the amount of cAMP released due to stimulation of LPA is critical if the 
receptor in question is LPA receptor 4.  Multiple trials were completed where the cells 
were stimulated with nothing for control, LPA, ADH, and forskolin for various times.  In 
each trial, a standard curve was created by comparing the standard cAMP concentration 
with their optical density values (Figure 16).  Then by graphing the optical density 
values of the LPA, ADH, and forskolin by interpolation, the cAMP concentrations could 
be determined.   
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The cAMP concentrations are expressed as cm2 (Figure 17).  Thus, contrary to our 
hypothesis, LPA does not stimulate an increase in intracellular cAMP levels.   
 
 
 
3.4   Fluid Secretion 
From the electrophysiology experiments it has been clear that there is a 
transepithelial ion flux in response to the basolateral addition of FBS, LPA, and human 
cyst fluid.  We next explored the hypothesis that the ion flux is accompanied by water 
flux.  The mpkCCDcl4 renal cells lines were grown to confluence for approximately 14 
days then the cells were stimulated basolaterally with LPA.  There were two different 
protocols for fluid secretion.  The first method was to leave the media completely 
untouched before stimulation.  Thus there was 2 mL of media on the basolateral side and 
1.5 mL of media on the apical side, this is the typical fluid level in the transwell chamber.  
The cells were stimulated LPA on the basolateral side of the cells or nothing for control 
and gently swirled for 5 minutes.  After five minutes the media was collected and placed 
in a pre-weighed microcentrifuge tube.  Thus after weighing the tube, by simple 
subtraction the amount of media was determined.  There was a statistically significant 
increase of 39 µL per transwell of media compared to the control (Figure 18).  In an 
alternative protocol, the cell volume was measured 24 hours after stimulation.  Since the 
stimulation occurred over such a long period of time, there was risk of losing fluid due to 
evaporation, thus oil was to the top of the transwell.  After 24 hours the fluid on top was 
collected and was centrifuged for 1 minute on max speed to separate the fluid and the oil, 
thus the oil could be removed before weighing the tubes.  In this long-term protocol there 
was a fluid secretion of approximately 50 µL per transwell compared to control (Figure 
19).   
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3.5   Rosiglitazone Data 
A previous study was performed using the PCK rat to determine the effect of oral 
feeding of the PPARγ agonist, pioglitazone, for 7 or 14 weeks. The 7 week pioglitazone 
feeding study was completed at the Mayo Clinic, while our laboratory in collaboration 
with Dr. Vincent Gattone, at the Department of Anatomy and Cell Biology, IUSM 
completed the 14 week protocol (3). PCK rats were either fed a control diet or a diet 
supplemented with pioglitazone at the concentration of 4 mg/kg for the 7 week study and 
20 mg/kg for both the 7 and 14 week studies.  The animals were sacrificed at the end of 
the 7 and 14 week study.  In the 14 week study, blood was collected by cardiac puncture 
for serum analysis. The left kidney and right liver lobe were collected and frozen in liquid 
nitrogen, whereas the remaining kidney and liver were fixed, then removed and kept in 
4% paraformaldehyde.  The kidney and liver were later embedded in paraffin and 
transversely sectioned and stained with hematoxylin, and eosin.  Cyst volume was 
calculated using point count stereology methods.  Fibrosis was assessed on a 1-4 scale (1 
was normal and 4 was severe) after completing a picrosirius red staining.  
Immunohistochemistry by light microscopy and immunocytochemistry by transmission 
electron microscopy were conducted to stain for the CFTR channel.  The results showed 
that there was improvement in the renal and liver cyst burden due predominantly to 
decreased cyst size.  There was a variation between the male and female rats used in the 
study.  The gender dimorphism in the animal mimicked the observations in humans, 
where renal disease is relatively worse in males and liver disease is relatively worse in 
females.  The serum analysis showed well-preserved kidney function, but liver enzymes 
were increasing indicating a compromised of hepatic function.  The bile ducts showed a 
decrease in apical expression of CFTR by electron microscopy (3).   
This study showed promising data, but some parameters where not assessed fully.  
For example, the fibrosis of the liver and kidneys were not severe enough to analyze 
effectively at 7 or 14 weeks of age in this slowly progressing model.  It is also important 
to determine whether there is a class action affect of PPARγ agonists on cyst growth in 
the PCK rat model.  Also, previous studies in renal cell culture studies have shown that 
the PPARγ agonists’ effect on CFTR occurs at a concentration lower than what is 
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necessary for diabetic treatment (4).  Thus, it was important to assess the effect of a low 
dose agonist.  Therefore, our laboratory used another PPARγ agonist, rosiglitazone, to 
investigate whether this compound would cause similar outcomes at a lower dose.   
Following weaning PCK rats were fed a control diet or a diet supplemented with 
rosiglitazone at three different concentrations, 4.0 mg/kg BW, 0.4 mg/kg BW, and 0.04 
mg/kg BW.  Only females were used in this 24 week study, due to gender dimorphism.  
Females developed more severe liver cystic disease, which in the previous pioglitazone 
study uncovered an area of concern, which we needed to follow.  There was no 
significant change in the glucose or hematocrit of the animals at any concentration 
indicating that the insulin-sensitizing drug did not cause hypoglycemia and did not cause 
fluid retention respectively (data not shown).  However, as shown in the body weight the 
animals supplemented with the highest dose, 4.0 mg/kg BW had a significant increase in 
their body weight compared to control, while the other two doses were not statistically 
different (Figure 20).   
 The body weight is perhaps a more sensitive measurement of fluid retention than 
hematocrits.  Total kidney weight (Figure 21A), was significantly lower in the highest 
and the lowest dose, but yet unchanged in the intermediate dose.  Kidney weight as a 
percent of body weight was determined for all animals.  Again, as seen in the total 
kidney weight, kidney weight as a percent of body weight was significantly decreased in 
the highest and lowest dose (Figure 21B), yet not statistically different in the 
intermediate dose.   
 Following point count stereology methods, the renal cyst volume was calculated 
as a percent of total kidney.  This provides a more accurate indication of how much of 
the total kidney weight is due to cystic burden.  From the renal cyst volume percentage 
the highest and lowest dose were significantly decreased, but a conflicting result was that 
the intermediate dose was actually significantly increased. (Figure 22A)  Taking the 
renal cyst volume percentage and multiplying it with the total kidney weight, the renal 
cyst volume was calculated.  Renal cyst volume showed the same statistical changes as 
the renal cyst volume percentage (Figure 22B).  It is even more apparent to see the 
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effects of the rosiglitazone when looking at the actual histological kidney sections 
(Figure 23).  Both the high and low dose decreased the cystic burden.   
 Other organs that were taken into account were the liver and the heart.  The organ 
that shows cyst development almost as frequently as the kidney is the liver, specifically 
the bile ducts.  Total liver weight (Figure 24A) was not significantly changed in any of 
the three different treatment doses.  Liver weight as a percent of body weight was 
determined, and as seen in total liver weight, neither of the three doses were significantly 
altered this parameter (Figure 24B).  Livers were stained with picrosiruis red to access 
the liver fibrocystic disease, by using point count stereology methods.  The percent liver 
fibrocystic disease (Figure 25) was not significantly different in any of the three doses. 
The serum liver enzymes, as measure of liver function, were also not significantly 
changed (data not shown).  PPARγ agonists have been widely noted for their fluid 
retention side effect, which is, in some cases severe enough to cause cardiac 
hypertrophy.  Thus the heart weight was determined (Figure 26).  Heart weight was not 
significantly changed in any of the three treatment doses.  The data is all summarized 
(Table 1). 
 A serum and urine analysis was performed on the samples collected from the 
animals at their 24 week time point.  For the serum the test detected sodium, potassium, 
chloride, CO2, anion gap, BUN, creatinine, calcium, phosphate, alanine transaminase 
(ALT), aspartate transaminase (AST), bilirubin, total protein, albumin, and glucose.  For 
the urine the test detected sodium, potassium, chloride, protein, and urea nitrogen.  No 
changes were observed in the serum and urine values (data not shown). 
 
 
 
3.6   Pioglitazone Data 
 The rosiglitazone data showed that PPARγ agonists had a class action effect and 
that a low dose was effective in the treatment of renal cyst burden.  But, another aspect 
of the preclinical trials of PPARγ agonists treatment, was to show that there is potential 
for the drug to be effective in a fast-progressing rat model, since previous studies were 
completed in the PCK rat, a slow-progressing rat model.  So the following study used the 
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W-WPK rat model, with pioglitazone, because it was shown in the previous studies to be 
less potent than the rosiglitazone.  Also it is important to determine a way to track the 
progress of the disease without sacrificing the animals, to be more relatable to treatment 
in humans.  So, CT scans would be used to determine the progress of the treatment and 
the disease along with histology to compare the two methods to determine if it is a 
reasonable to use CT scans to determine the extend of renal cyst burden. 
 W-WPK rats were given grape juice or grape juice supplemented with 
pioglitazone at two different concentrations, 20 mg/kg BW and 2.0 mg/kg BW starting 
on day 5.  All animals were started on the drug at 5 days of age, because it was difficult 
to determine which of the animals were cystic or normal.  Animals were continued on 
the treatment until it was determined if they were actually cystic or normal.  Animals 
were sacrificed at two time points, either at 10 days or at 18 days, and of the animals a 
subset were chosen for CT imaging.   
 The 10-day data were collected in order to determine if the disease could be 
assessed in an earlier stages.  There was no significant change in the glucose or 
hematocrits of the animals fed either concentration indicating that the insulin-sensitizing 
drug did not cause hypoglycemia or fluid retention (Figure 27A,B).  Unlike the 
rosiglitazone data, in the 10 day animals there was no change in body weight (Figure 28) 
in either of the treatments compared to control.  After only being on treatment for 5 
days, the only kidney parameter in which drug treated was different from control was 
kidney weight as a percent of body weight (Figure 29B).  High dose treatment, 2.0 
mg/kg BW pioglitazone, was significantly increased.  Total kidney weight (Figure 29A) 
remained unchanged between the different treatments.  Renal cyst volume percentage 
determined by point count stereology methods (Figure 30A), and the renal cyst volume 
(Figure 30B) determined by taking the percentage multiplied with the total kidney 
weight both remained statistically unchanged in the drug treated animals compared to 
control.   
 Other organs taken into account were the liver and heart.  For total liver weight 
(Figure 31A) and for liver weight as a percent of body weight (Figure 31B) just as seen 
in the kidney, neither dose was statistically different from control.  Total heart weight 
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was statistically increased for both the high and low dose treatment (Figure 32A), but 
when looking at heart weight as a percent of body weight (Figure 32B) there was no 
statistically significant changes.    
 The extra parameter that was different from all the previous PPARγ agonist 
studies was the use of CT scans.  From the CT scans, a 3-dimensional image was 
developed for both the cystic tissue and the normal tissue, and the program was able to 
determine the volume in cubic millimeters.  Thus the percent renal cyst volume could be 
determined.  In the 10 day animals there were no statistically significant changes, but 
also the n values were low for this group of animals, because based in the data provided 
above, we did not expect to find differences (Figure 33).  All the 10 day data is 
summarized (Table 2). 
 The 18 day data was collected as the end of the study to examine the full effect of 
the disease.  Since it was a fast progressing animal model, at this time point the animals 
were close to renal failure.  Blood glucose was statistically decreased for both the low 
and high dose treated animals (Figure 34A).  Interestingly, this is the first model where 
we have observed a change in glucose.  Hematocrits were not statistically different 
(Figure 34B), indicating that fluid retention was not a problem with the pioglitazone 
treatment.  Body weight was not statistically different in animals treated with either dose 
compared to control (Figure 35).  After these animals were on treatment for longer 
period of time, unlike the animals sacrificed on 10 days of age, there was more 
interesting changes in the kidney parameters.  Total kidney weight (Figure 36A) was 
statistically decreased for the low dose treatment, and trended lower in high does as well, 
but not statistically.  Kidney weight as a percent of body weight was not statistically 
different, but the low dose was definitely trending in the decreasing direction (Figure 
36B).  The renal cyst volume percentage calculated by point count stereology was not 
statistically different in either the low or high dose animals, but again both of them were 
decreasing compared to control (Figure 37A).  Using the renal cyst volume percentage 
and the total kidney weight, the cyst volume was determined for this parameter, low 
dose significantly decreased the cyst burden (Figure 37B).   
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 Other organs that were taken into account were the liver, heart, and brain.  For 
total liver weight (Figure 38A) and for liver weight as a percent of body weight (Figure 
38B), there was no statistical difference between the treatment groups and the control.  
Total heart weight (Figure 39A) was significantly decreased for the low dose treatment 
group, but heart weight as a percent of body weight (Figure 39B) was not significantly 
different.  This specific animal model develops severe hydrocephalus along with the 
cystic kidney disease, thus the brain was analyzed by measuring the perimeter of the 
ventricles and the brain area.  In both cases there was no significant difference in brain 
perimeter or brain area (Figure 40A,B). 
 Just as in the 10 day animals, some of the 18 day animals received CT scans. 
From the CT scans a 3-dimensional image was developed for both the cystic tissue 
(Figure 41) and the normal tissue (Figure 42).  The 3-dimensional images were 
developed by assigning the appropriate CT values and building the kidney slice by slice, 
by removing everything from the image except the kidney tissue.  This method is shown 
for the cystic tissue in which the colored section, determined from the CT number range, 
only marks cyst tissue (Figure 43).  The CT number range was also applied for normal 
tissue, which the colored areas only showed the normal, functioning renal tissue (Figure 
44).  Then by using the Philips program, once the CT number range was applied for 
either cyst or normal renal tissue, the kidney was segregated by removing all the areas 
besides the kidney of interest (Figure 45).  The Philips program was able to determine 
the volume in cubic millimeters based on the 3-dimensional image produced.  Thus the 
percent renal cyst volume could also be assessed.  In the 18 day animals there was no 
statistically significant changes (Figure 46), but the treated animals were showing a trend 
of decreasing renal burden.  The 18 day data is all summarized (Table 3). 
 One of the most important aspects of this study, besides the drug treatment, was 
the use of the CT scans to access the progress of the disease and if it was comparable to 
the histological analysis.  Using regression statistics on the renal cyst volume percentage 
calculated from the CT scans and the renal cyst volume percentage calculated from the 
histology showed an R2 value of 0.6993 and a correlation of 0.8362.  The CT scans can 
further be compared with the whole animal, by showing the correlation of the left kidney 
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weight to the total left kidney volume determined from the CT scans, which showed an 
R2 value of 0.9719 and a correlation of 0.9859.  Finally by taking the total kidney weight 
and multiplying the renal cyst volume percentage determined using point count 
stereology and comparing that volume to the CT cyst volume it showed a R2 value of 
0.9360 and a correlation of 0.9674. 
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CHAPTER 4. DISCUSSION 
 
 
 
4.1   Electrophysiology 
 Electrophysiology is a useful tool for following transepithelial electrogenic ion 
flux.  Our laboratory has been studying the effects of human cyst fluid with goals of 
identifying the active component, which was previously stated as a lipid-like molecule, 
and to characterize the intracellular pathway stimulated in response to cyst fluid (14).  
Human cyst fluid is normally in contact with the apical side of the renal epithelial cells, 
thus one would wonder why does a person who has had cysts their whole life not go into 
renal failure until midlife.  Previous studies had reported that cyst fluid stimulated 
transport when added to either side of the polarized epithelial cells.  Our laboratory 
decided to investigate this question further, using the mpkCCDcl4 renal cell line.  Human 
cyst fluid (10%) was added to the both the apical and basolateral side of the cells.  In 
contrast to previous studies, there was no reaction to human cyst fluid when the cells 
were explored on the apical side, but instead there was a response when applied to the 
basolateral side.  The ion transport response was relatively complex consisting if several 
temporally distinct components (2).  This suggested that the human cyst fluid reacted 
with the epithelial plasma membrane on the outside of the cyst.  The question was how 
could the cyst fluid reach the basolateral side and what importance does this have to the 
renal failure in midlife.  This lead to the hypothesis that when the cysts become too large 
they begin to leak or burst releasing cyst fluid into the abdominal cavity, causing the cyst 
fluid to come into contact with basolateral side of the cystic, renal cells.  The subsequent 
increase in ion flux accompanied by compensatory water movement causes the 
expansion of the remaining intact cysts.  This could also occur in response to renal 
injury.
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Before more experiments could be completed, human cyst fluid was tested to 
determine which cyst fluid was most active and could be used for other experiments.  
Cyst fluid from different human patients was added basolaterally to determine which 
samples gave an optimal response.  One thing that was consistent was cyst fluid that had 
blood contamination, even after centrifuging, was not that active.  The results suggest that 
the red blood cells may contain a factor that inactivates the stimulatory component.  After 
the testing, it was determined that human cyst fluid 12 (CF-12) had an optimal response 
and there was plenty of it to complete multiple experiments. 
 Previous studies showed that the response seen after the addition of human cyst 
fluid was not due to sodium absorption, but it was due to chloride secretion (2).  It is also 
well documented that cyst expansion is due to chloride secretion via CFTR (10, 24).  
However a variety of studies including the complex response observed in our 
electrophysiological experiments suggested the presence of additional channels.  On 
prime candidate for an additional transporter is the recently described Ca2+-activated 
chloride channel (CaCC), TMEM16A.  This was investigated using various inhibitors in 
electrophysiology experiments.  The two compounds we used were GlyH-101 which 
specifically inhibit CFTR (23), and tannic acid, which has been recently described to 
inhibit TMEM16A (25,26).  The renal epithelial cells were pretreated with the two 
inhibitors, both separately and in combination before the addition of CF-12.  The results 
suggested that the first transepitheilial ion flux indicated by the first peak was due 
predominantly to chloride secretion via CFTR, because the inhibitor GlyH-101 inhibited 
majority of the ion transport event indicated by the first peak.  The second, broader ion 
transport event, indicated by the second peak, most likely represented chloride secretion 
via TMEM16A, because tannic acid inhibited majority of the ion transport event, 
indicated by the second peak.  When the inhibitors were added together almost the entire 
response was inhibited.   
 It was recently discovered by our laboratory that LPA was the active component 
in human cyst fluid (2).  LPA and human cyst fluid both generate identical responses 
each with multiple components.  An LPA dose response study was completed and it was 
determined that the LPA concentration of 0.05 to 50 µM maximally stimulated ion 
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transport in the mpkCCDcl4 cells.  We also used the chloride channel inhibitors to 
determine the inhibitory effects compared with the cyst fluid.  The GlyH-101 inhibitor 
almost completely inhibited all stimulated transport.  These results suggested that there 
might be a correlation between the CFTR and TMEM16A.  Further experimentation will 
be necessary to fully characterize the transporters and any interactions between them.  
 Fetal bovine serum (FBS) contains maximal concentration of LPA and we have 
used this as a more available alternative to cyst fluid.  FBS showed the same transport 
responses that were seen when either cyst fluid or LPA were added basolaterally.  To 
further ensure that FBS acts in the same way as cyst fluid and LPA, the chloride channel 
inhibitors, GlyH-101 and tannic acid, were used.  As seen when cyst fluid and LPA were 
pretreated with the inhibitors, FBS showed the same type of inhibitory response.  
 Previous data suggests that the two chloride channels may be functionally 
dependent on each other.  Therefore it is reasonable to look at the CFTR or the CaCC 
channel more in detail. Since the CaCC’s are dependent on Ca2+ activation of this 
channel.  Ca2+ can be looked at in more detail by using compounds that alter intraceullar 
Ca2+.  Ionomyocin increases intracellular Ca2+, by enhancing Ca2+ influx from 
extracellular fluid.  Bapta-AM decreases intracellular Ca2+ by chelating intracellular 
Ca2+.  One would expect that ionomyocin would potentiate the CaCC’s, and that Bapta-
AM would inhibit the same channel.  The results were somewhat more complex.  When 
ionomyocin was added there was an immediate increase in transepithelial transport.  
However, after the addition of either LPA or human cyst fluid, the normal stimulated ion 
movement was decreased. It is likely that the addition of ionomyocin stimulated the 
CaCC in the absence of LPA and cyst fluid stimulation and no further activation of this 
channel was possible by LPA or cyst fluid.  With the pretreatment of Bapta-AM 
followed by LPA or human cyst fluid the reactions were similar and showed inhibition 
of all components of the stimulated transport.  These results suggest that Ca2+ is involved 
in all aspects of the chloride secretory response including CFTR-mediated transport.  
Since Ca2+ regulation of CFTR is unusual this may indicated that there is a correlation 
between CFTR and CaCC in the renal cells.  
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The identity of the CaCC remains unknown, but previous inhibitor experiments 
suggested that it may be TMEM16A. It has been suggested that there are more specific 
inhibitors for TMEM16A than the previously used tannic acid.  They were T16Ainh-A01 
and digalliac acid.  When the cells were pre-treated with either inhibitor, there was no 
effect on the FBS and human cyst fluid stimulated current, thus indicating at least in the 
mpkCCDcl4 cell line, that these inhibitors are not effective.  This finding is surprising, 
because immunohistochemical studies indicate a high abundance of TMEM16A in the 
cell line.  We have requested additional specific inhibitors, and these will be explored in 
subsequent experiments. 
Knowing that cyst fluid and LPA stimulates a chloride secretory response, it was 
important to identify the LPA receptor which initiates the response.  There are 5 known 
LPA receptors with a 6th postulated (9).  LPA receptor 5 was investigated by comparing 
the response of ester LPA against ether LPA.  Ether LPA is known to preferentially 
stimulate LPA receptor 5, so if ether LPA addition resulted in the chloride secretory 
response, then the intracellular pathway by which LPA stimulates fluid secretion is by 
LPA receptor 5.  Ultimately ether LPA did not show the characteristic response that is 
seen when human cyst fluid is added basolaterally, suggesting the receptor in question is 
not LPA receptor 5.  The receptors were further investigated by using LPA receptor 1 and 
3 antagonists, Ki16425 and VPC51299.  The antagonists were added basolaterally, 
followed by the addition of LPA.  Antagonist pretreatment did not alter a subsequent 
LPA response suggesting that the receptor in question is not LPA receptor 1 or 3.  The 
laboratory previously showed that LPA receptor 2 was not likely the receptor either, by 
pretreating the mpkCCDcl4 renal cells with DDP (dodecylphosphate) an LPA2 agonist/ 
LPA3 antagonist, which had no effect on cyst fluid stimulated ion transport (2).  By 
process of elimination the receptor experiments suggest that LPA receptor 4 is the only 
receptor in which the intracellular signaling pathway can occur, unfortunately there is not 
a known agonist or antagonist of LPA receptor 4.  To further these studies we have 
requested more specific agonists and antagonists from GSK. 
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4.2   Immunohistochemistry 
 TMEM16A is a relatively new CaCC and it might play a bigger role in the 
principal renal epithelial cell function than previously noted. So showing the presence of 
TMEM16A in the mpkCCDcl4 renal cell line is critical.  Confluent cells were stained for 
the TMEM16A protein, and the results strongly agreed that there is TMEM16A in the 
cells.  The data shows that there is a lot of TMEM16A throughout all the renal cells, and 
that majority of it is concentrated on the apical membrane.  It will also be important to 
determine if TMEM16A is located in other tissue, besides mouse, such as rat and human 
tissue.   
 
 
 
4.3   cAMP 
 According to Choi, the only LPA receptor that signals through the cAMP pathway 
is LPA receptor 4 (9).  Based on our finding that CFTR is activated in response to LPA 
and the well-documented knowledge that the main component that activates CFTR in the 
phosphokinase-A (PKA) phosphorylation after PKA activation by increasing cAMP, we 
assumed that LPA 4 was the most likely receptor candidate.  It happens that the LPA 
receptor 4 is also the only one of the receptors that does not have a known agonist or 
antagonist available.  If we stimulate the cells with LPA and then perform a cAMP assay 
on them and there is an increase in cAMP, we can predict that it is likely the receptor in 
question responsible for the chloride secretion seen with the addition of LPA is working 
through LPA receptor 4.  Thus the cells were stimulated with LPA for 1 and 5 minutes.  
Unexpectedly in all cases the cAMP levels were the same or lower than control, 
indicating that LPA might actually inhibit cAMP.  According the Choi, LPA receptor 4 
actually can inhibit the cAMP pathway as well as stimulate it (9).  However, these 
results are contrary to what is expected for an agent that increases CFTR activity.  Thus 
there was a cAMP assay completed on the cells stimulated with LPA for only 20 
seconds.  The cAMP levels were still the same as the control.  At this point, it was 
critical to make sure the methodology was working correctly.  Agents that are known to 
increase cAMP where used to stimulate the cells, namely forskolin and ADH.  With 
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stimulation of both forskolin and ADH there was an increase in cAMP levels as 
predicted, thus indicating the methodology was working and that LPA does not stimulate 
an increase in cAMP levels.   
 Overall, the cAMP assay raises multiple questions.  Initially, it indicates that the 
receptor in question may not be LPA receptor 4.  This also now contradicts the 
electrophysiology data which correlated with the LPA receptor not being 1,3, or 5 and 
our laboratory also already showed that it was not LPA receptor 2 (2).  Thus, in the 
future our laboratory will need to reassess which receptor is responsible for the secretory 
response associated with the basolateral addition of LPA.  We are in the process of 
requesting a variety of receptor agonists and antagonists from GSK.  These are not 
commercially available.  Another question the cAMP assay presents is whether or not 
the LPA stimulates chloride secretion via CFTR.  Previous electrophysiology inhibitor 
studies indicated that the chloride secretory response was due to a combination of both 
CFTR and CaCC.  CFTR has been well documented that it is activated by the adenylyl 
cyclase, cAMP pathway (2), while according to the assay with the addition of LPA there 
was no cAMP present.  This presents a problem that potentially the inhibitors being used 
in electrophysiology were not as specific as they were indicated to be, and may have 
potentially inhibited both CFTR and CaCC.  In this case we have also requested 
additional, more specific, but not commercially available inhibitors from a colleague. 
 
 
 
4.4   Fluid Secretion 
 Electrophysiology is an extremely useful tool in determining net ion flow, then 
with the use of inhibitors and enhancers, the nature of the particular channel can be 
determined.  The data has strongly supported that there is chloride secretion after the 
addition of LPA to the basolateral side of the cells.  LPA is the active component of 
human cyst fluid and the hypothesis is that when a LPA is released and allowed to come 
into contact with the outside of the cyst, this causes chloride ions to be secreted and the 
cyst begin to expand.  This hypothesis assumes that fluid follows the chloride ions that 
are being secreted, but electrophysiology cannot determine the net fluid flow.  Thus, a 
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protocol was developed to determine the amount of fluid secreted, if any.  There were 
multiple ways to approach the fluid secretion, and all methodology that were used 
showed the same results, that there was actual fluid secretion following the stimulation 
of LPA on basolateral side of the cells.  In one method LPA was added and then after 5 
minutes of stimulation the media was collected and weighed.  In this method the cells 
were not stressed before stimulation, because the media was changed 24 hours prior to 
the fluid removal.  There was a secretion of approximately 39 µL per transwell from the 
basolateral to the apical side of the cells, thus showing that LPA also stimulates fluid 
secretion, which would cause a cyst to expand. In this first series of experiments the 
fluid secretions were done in a 5 minute time frame, because according to the 
electrophysiology data, the chloride secretion occurs immediately after the addition of 
LPA.  However, one would assume that fluid secretion would continue over time, so a 
fluid secretion study that allowed the cells to be stimulated for LPA for 24 hours was 
completed.  The data does support that fluid continues to secrete over 24 hours, but not 
much more was secreted compared to the fluid collected after 5 minutes.  It went from 
secreting 39 µL per transwell in 5 minutes to 50 µL per transwell in 24 hours.  Thus it 
appears that majority of the fluid secretion happens rather quickly.  Fluid secretion does 
support the hypothesis that LPA is the active component of cyst fluid when in comes 
into contact with the basolateral side of the cyst.  
 
 
 
4.5   Rosiglitazone Data 
The previous study performed using the PCK rat determined the effect of oral 
feeding of the PPARγ agonist, pioglitazone, for 7 or 14 weeks.  PCK rats were either fed 
a control diet or a diet supplemented with pioglitazone at the concentration of 4 mg/kg 
for the 7 week study and 20 mg/kg for both the 7 and 14 week studies.  The results 
showed that there was improvement in the renal and liver cyst burden due predominantly 
to decreased cyst size.  There was a variation between the male and female rats used in 
the study.  The serum analysis showed well-preserved kidney function, but liver enzymes 
were increasing indicating a compromised of hepatic function.  The effect of pioglitazone 
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on fibrosis was more difficult to assess, since fibrosis is mild in this early stage of the 
disease.  The bile ducts showed a decrease in apical expression of CFTR by electron 
microscopy (3). This study showed promising data, but some parameters where not 
assessed fully.  For example, the fibrosis of the liver and kidneys were not severe enough 
to analyze effectively at 7 or 14 weeks of age in this slowly progressing model.  It is also 
important to determine whether there is a class action affect of PPARγ agonists on cyst 
growth in the PCK rat model (3).  Also, previous studies in renal cell culture studies have 
shown that the PPARγ agonists’ effect on CFTR occurs at a concentration that is 
approximately 10 fold lower than the EC50s for receptor transactivation (2).  Thus, it was 
important to assess the effect of a low dose agonist.  Therefore, our laboratory used 
another PPARγ agonist, rosiglitazone at three different concentration; 4 mg/kg BW, 0.4 
mg/kg BW, and 0.04 mg/kg BW, to investigate whether this compound would be 
effective at a lower dose.  Rosiglitazone is more potent than pioglitazone, thus 4.0 mg/kg 
BW rosiglitazone is analogous to 20 mg/kg BW pioglitazone.  The PCK rats were treated 
from post-weaning, approximately 3 weeks, until 24 weeks of age	  with	  0	  mg/kg	  BW,	  4 
mg/kg BW, 0.4 mg/kg BW, and 0.04 mg/kg BW rosiglitazone.	   
There was no significant change in the blood glucose for any dose as well as no 
change in hematocrit.  No change in hematocrit was a promising result, because it 
indicates that the rosiglitazone is potentially not causing the well-known side effect of 
fluid retention.  The heart weight was also not altered by drug treatment, thus further 
indicating that the drug was not causing fluid retention.  A conflicting result with the 
hematocrit was the total body weight.  It was not affected in either the intermediate or in 
the low dose, but it actually was significantly higher in the high dose.  The increase of 
body weight could have been due to an increase in fluid retention because of the high 
dose drug treatment, which was not severe enough to alter heart weight or hematocrit.  
There was another difficulty with this high dose that affects all results of the study.  High 
dose, or 4.0 mg/kg BW, treated animals only had an n of 3, because 7 of the animals were 
removed from the study due to the development of cholangitis, an infection of the 
common bile duct.  Even though many of the high dose treated animals developed 
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cholangitis, the liver fibrocystic disease was not statistical different for any of the three 
doses, but again the cholangitis animals were removed from the statistical analysis.    
Even taking the problems with the high dose into account, the data related to the 
kidney and the cystic volume showed promising data.  In all renal parameters, the lowest 
dose, 0.04 mg/kg BW, was significantly effective.  This indicates that the drug is 
working, so it is a class action in the PPARγ agonists, since both rosiglitazone and 
pioglitazone worked in a similar fashion by decreasing the renal cystic burden.  Also, a 
extremely important piece of data was that the lowest dose of treatment, which was two 
ten-fold decrease compared to the concentration used in the pioglitazone study, was 
effective in decreasing the renal cystic burden.  As noted in some of the renal parameters, 
the intermediate dose actually significantly increased cystic burden, and currently reasons 
are still unknown. 	  	  	  
4.6   Pioglitazone Data 
 Following the rosiglitazone study, it was determined that it was important to look 
at another rat model as well as determine a more effective way to track the progress of 
the disease.  For maximal contrast to the slow-progressing PCK rat we chose the fast-
progressing model the W-WPK rat.  Also, this study added a new research parameter by 
introducing CT scans.  Previously the severity of the disease and the effectiveness of the 
PPARγ agonists was determined through histological analysis, after the animal was 
sacrificed.  Thus, if this study were to go into human clinical trials there would have to 
be another way to track the progress of the disease, and one way to do this would be CT 
scans if they proved to be effective.  Also, it was clear that the rosiglitazone had more 
side effects than the pioglitazone in the PCK rat, so the study also went back to using the 
PPARγ agonist, pioglitazone.  
 In the WPK model the disease progressed so rapidly that by day 18 their kidneys 
were approximately 15% of the body weight (Figure 29B).  All animals had to be treated 
at the age of 5, because it was nearly impossible, by palpation, to determine whether 
individual animals were cystic or normal.  Once the animals were on treatment, by 
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approximately day 9 it is easy to determine which ones were cystic, and eventually the 
treatment numbers were reduced.  The first time point was 10 days when the animals had 
been on treatment for 5 days.  At this time point glucose and hematocrit were not 
different, indicating that the animals are not hypoglycemic or retaining fluid, which was 
further substantiated by the consistency in body weight.  The only renal parameter that 
was significantly different was the high dose kidney weight as a percent of body weight, 
in which it was increased in comparison with the control.  This is the opposite of the 
expected finding if the drug is working properly to decrease renal cystic burden.  
 The total liver weight and liver weight as a percent of body weight was 
statistically not different.  The heart weight was actually significantly increased at both 
the high and low dose.  This indicates that potentially the drug is causing fluid retention, 
even if not seen in the hematocrit or body weight.  However, heart weight as a percent of 
body weight was not significantly changed.  The one important aspect of the 10 day time 
point was the CT renal cyst volume percentage.  The renal cyst volume percentage 
calculated by histology resembled CT renal cyst volume.  In both cases the low dose 
treated animals decreased in compared to the control animals, which is a trend that was 
seen in the rosiglitazone 24-week study.	  	   
 The 18 day time point showed promising results throughout all parameters, even 
if they were not all significant.  Blood glucose was significantly decreased at both high 
and low dose, indicating that potentially these animals are hypoglycemic.  The 
hematocrit was not different, thus indicating that the animals are not experiencing the 
fluid retention side effect associated with the PPARγ agonists.  And further agreeing 
with the hematocrit data, the heart weight was significantly decreased for low dose and 
was decreasing for high dose.  Heart weight as a percent of body weight was not 
significantly different.  Ultimately it seems that the fluid retention side effect is not an 
issue with the W-WPK rat.  Liver weight and liver weight as a percent of body weight 
were not different.  Most important was the renal parameters, in which there was very 
little that was statistically significant, but their trends showed great promise.  Total 
kidney weight trended lower for each treatment group, even was significantly lower in 
the low dose treated animals.  Kidney weight as a percent of body weight was showing 
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the trend that the low does was more effective than the high dose.  Renal cyst volume 
percentage calculated from the histological sections did not show any statistical 
difference, but did show the trend that was seen in the rosiglitazone study, where the low 
dose was more effective than the high dose.  Renal cyst volume was statistically lower 
than the control for the low dose treated group.  Ultimately the kidney data showed 
promising trends that were consistent with what was seen in the previous rosiglitazone 
study.  The low dose was more effective in the treatment of renal cystic burden.   
 The W-WPK rat developed hydrocephalus along with the renal cystic disease, 
thus it was important to make sure that the PPARγ agonists were not affecting the 
hydrocephalus.  To measure the severity of the hydrocephalus the brain perimeter and 
area were determined.  The ventricles were measured using the histological sections.  
Neither the brain perimeter nor area were different due to the pioglitazone treatment, 
thus indicating that PPARγ agonists do not affect the cerebral spinal fluid accumulation 
in the brain.  These animals were also imaged at the 18 day time point and their CT 
images were analyzed to determine the renal cyst volume percentage.  Similar to what 
was seen in the kidney parameters, the CT renal cyst volume percentage had a trend 
where the low dose was more effective than the high dose.   
 Overall, one of the most important parts of the study was the CT scans.  If the 
study is to go to human clinical trials, there has to be an effective way to track the 
progress of the disease during the course of treatment.  CT imaging is a good method to 
use for many reasons, it is less expensive and takes less time compared to an MRI and 
can be used on any patient (51) and is able to create a 3-dimensional image of the 
kidney.  The best way to determine if the CT scans were comparable to the histological 
sections was to determine the correlation between multiple different CT parameters.  
First we directly compared the CT renal cyst volume percentage with the renal cyst 
volume percentage determined from histology.  Next we compared the kidney weight 
with the total volume determined from the CT.  Finally, the cyst volume from CT was 
compared with the cyst volume determined from the mass of the kidney and the renal 
cyst volume percentage.  Overall, the correlation was good, thus indicating CT scans are 
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can be used effectively in analyzing renal cyst burden of the rat, and thus should be able 
to be used in humans.   
In conclusion all the animal preclinical data, indicate that PPARγ agonists may be 
effective in decreasing cyst growth.  The results were positive in the low dose treatment, 
which is the dose that would be more beneficial, because of the side effects associated 
with high dose PPARγ agonists.  Also, it is clear that CT scans could be used throughout 
PPARγ treatment to track the disease and progress of the renal cyst burden.  So the next 
step is to take PPARγ agonist to phase 1 human clinical trails to see if the results that 
have been seen in the rat models can be reproduced in humans.    
 
	   40 
CHAPTER 5. SUMMARY 
 
 
 
 Treatment for polycystic kidney disease currently is limited, and drugs that are in 
clinical trials are either not showing efficiency, or they are not patient friendly, so the 
ultimate goal was to develop new targets for potential therapies.  Treatment could be for 
the early onset of the disease, thus a long term drug therapy, or it could be late stage 
treatment.   
The LPA study is targeting the late stage of the disease.  The hypothesis that once 
the cyst have expanded and become so large that they burst or leak, which could also 
occur due to renal injury, the cyst fluid would stimulate the other cyst to secrete fluid.  
This is consistent with the clinical observations that once renal decline beings, the disease 
progresses to end-stage renal failure rather quickly.  LPA was determined to be the active 
component of cyst fluid, thus studying the pathway by which LPA stimulates the chloride 
secretion could eventually lead to a drug that targets the last stage of disease progression.  
My results suggest that LPA is stimulating chloride and fluid secretion via a combination 
of CFTR and CaCC and that the two channels may be functionally linked.  The secretion 
is not occurring through a cAMP stimulated pathway and potentially TMEM16A is 
playing a larger role than expected.  The LPA receptor has still not been identified.  
Ultimately, the LPA story is still being developed, but has becoming intriguingly 
interesting. 
The PPARγ agonist study was looking at long-term treatment that begins earlier 
in the disease and continues as life-long treatment.  By electrophysiology and inhibitor 
studies, it was previously discovered the PPARγ agonists decrease synthesis of CFTR 
(28).  CFTR has been determined to be the channel responsible for cyst growth, so it was 
logical to study the effects of PPARγ agonists in the treatment of PKD.  Thus, our 
laboratory along with the Mayo Clinic completed a preclinical animal trial using the PCK 
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rat and pioglitazone and the results were promising.  My studies begun with further 
studying the PPARγ agonists, completing a long-term study, using rosiglitazone at three 
different doses and adding a different rat model.  The data were encouraging, first of all 
the rosiglitazone proved to be effective thus indicating that there is a class action of 
PPARγ agonists in the treatment of PKD.  Also, in multiple experiments the low dose 
agonists proved to be effective, which is extremely important, because PPARγ agonist are 
associated with a dose dependent side effect of fluid retention.  The next step was to 
determine if the PPARγ agonist were effective in another rat model with a different 
genetic mutation, that was fast-progressing, and ultimately determine a way to track the 
disease that could be used in human patients.  My results suggested that pioglitazone was 
not as significantly effective in the W-WPK rat model as it was in the PCK rat model, but 
that there was a trend that the low dose was showing promise in agreement with the 
rosiglitazone data.  More importantly CT scans were used to track the progress of the 
disease and were compared with the histological data, which it was promising results.  
There was a strong correlation between the CT and the histological analyses, thus 
suggesting if this study was to go to human clinical trials, CT scans could be used to 
analyze and track the progress of the disease.  The next step to the story is to, hopefully, 
go into human clinical trials.  
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Table 1: Summary of overall data completed for the 24 week, rosiglitazone study on the PCK rat model.. 	  
PCK rats were fed a control of rosiglitazone-supplemented diet (mg/kg BW) for a total of 24 weeks). The values given are 
averages ± SEM. 
Abbreviations in the table include: KW% BW: total kidney weight as a percentage of total body weight; LW% BW: liver weight 
as a percentage of total body weight.  
P-values are for the comparison of control versus rosiglitazone-supplemented diets by Anova, one-way test a P value less than .05 
is considered significant. NS: not significant, S: Significant. 
 
24 Week Diet Control Rosiglitazone Significance Rosiglitazone Significance Rosiglitazone Significance 
 
Diet 4.0mg/kg BW 
 
0.4 mg/kg BW 
 
0.04mg/kg BW 
 
 
n=12 n=3 
 
n=8 
 
n=8 
 Body Weight 
(BW) g 340.68 ± 5.55 378.5 ± 2.47 S 338.94 ± 6.94 NS 342.11 ± 10.10 NS 
Kidney Weight 
(KW) g 4.33 ± 0.18 3.56 ± 0.26 S 4.27 ± 0.22 NS 3.68 ± 0.14 S 
KW % BW 1.22 ± 0.04 0.94 ± 0.06 S 1.27 ± 0.08 NS 0.95 ± 0.15 S 
% Cyst Volume 12.70 ± 1.32 7.58 ± 0.72 S 18.53 ± 2.55 S 8.49 ± 1.92 S 
Renal Cyst 
Volume (mL) 0.53 ± 0.06 0.27 ± 0.05 S 0.82 ± 0.14 S 0.33 ± 0.09 S 
Liver Weight 
(LW) g 23.11 ± 1.44 22.66 ± 5.39 NS 22.05 ± 2.07 NS 24.23 ± 0.10 NS 
LW % BW 6.77 ± 0.43 5.97 ± 1.38 NS 6.50 ± 0.57 NS 7.11 ± 0.27 NS 
Liver % 
Fibrocystic 31.10 ± 2.02 36.17 ± 0.38 NS 36.81 ±3.61 NS 35.36 ± 3.74 NS 
Heart Weight 
(HW) 1.29 ± 0.03 1.25 Ns 1.15 ± 0.05 NS 1.23 ± 0.03 NS 
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Table 2: Summary of overall 10 day data completed for the pioglitazone study on the W-WPK rat model.   
 
W-WPK rats were fed a control of pioglitazone-supplemented diet (mg/kg BW) from day 5 until day 10 of age.  The values given 
are averages ± SEM. 
Abbreviations in the table include: KW% BW: total kidney weight as a percentage of total body weight; LW% BW: liver weight 
as a percentage of total body weight; HW%BW: heart weight as a percentage of total body weight. 
P-values are for the comparison of control versus poiglitazone-supplemented diets by Anova, one-way test a P value less than .05 
is considered significant. NS: not significant, S: Significant. 
 
W-WPK 10 Day Control Pioglitazone Significance Pioglitazone Significance 
 
Diet 20.0 mg/kg BW 
 
2.0 mg/kg BW 
 
 
n=7 n=2 
 
n=4 
 Glucose (mg/dL) 343 ± 43.962 298 ± 32 NS 312.75 ± 67.24 NS 
 
n=7 n=6 
 
n=5 
 Hematocrit 26.13 ± 0.65 25.81 ± 1.08 NS 26.28 ± 0.99 NS 
 
n=9 n=6 
 
n=5 
 Body Weight (BW) g 18.61 ± 0.881 18.97 ± 1.046 NS 20.732 ± 0.66 NS 
Kidney Weight (KW) g 0.607 ± 0.074 0.703 ± 0.073 NS 0.748 ± 0.059 NS 
KW % BW 3.20 ± 0.15 3.67 ± 0.20 S 3.59 ± 0.21 NS 
% Cyst Volume 45.125 ± 2.104 46.99 ± 2.92 NS 44.042 ± 4.42 NS 
Renal Cyst Volume (mL) 0.278 ± 0.036 0.337 ± 0.0498 NS 0.338 ± 0.0586 NS 
 
n=7 n=5 
 
n=5 
 Liver Weight (LW) g 0.663 ± 0.036 0.676 ± 0.04 NS 0.714 ± 0.02 NS 
LW % BW 3.54 ± 0.14 3.16 ± 0.15 NS 3.46 ± 0.16 NS 
Heart Weight (HW) 0.143 ± 0.005 0.168 ± 0.007 S 0.166 ± 0.005 S 
HW % BW 0.77 ± 0.04 0.91 ± 0.07 NS 0.80 ± 0.02 NS 
 
n=2 n=2 
 
n=1 
 Renal Cyst Volume (CT 
Scans) 41.891 ± 0.809 46.457 ± 12.15 NS 41.204 NS 
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Table 3: Summary of overall 18 day data completed for the pioglitazone study on the W-WPK rat model.   
 
W-WPK rats were fed a control of pioglitazone-supplemented diet (mg/kg BW) from day 5 until day 18 of age.  The values given 
are averages ± SEM. 
Abbreviations in the table include: KW% BW: total kidney weight as a percentage of total body weight; LW% BW: liver weight 
as a percentage of total body weight; HW%BW: heart weight as a percentage of total body weight. 
P-values are for the comparison of control versus poiglitazone-supplemented diets by Anova, one-way test a P value less than .05 
is considered significant. NS: not significant, S: Significant. 	  
W-WPK 18 Day Control Pioglitazone Significance Pioglitazone Significance 
 
Diet 20.0 mg/kg BW 
 
2.0 mg/kg BW 
 
 
n=11 n=8 
 
n=10 
 Glucose (mg/dL) 255.7 ± 16.6 193 ± 8.91 S 213.4 ± 13.0 S 
Hematocrit 28.83 ± 1.12 28.89 ± 0.76 NS 27.45 ± 1.17 NS 
Body Weight (BW) g 29.91 ± 2.11 26.41 ± 0.677 NS 27.02 ± 0.948 NS 
Kidney Weight (KW) g 4.51  ± 0.477 4.22 ± 0.13 NS 3.53 ± 0.1704 S 
KW % BW 14.94  ± 1.02 16.01 ± 0.45 NS 13.23 ± 0.78 NS 
% Cyst Volume 74.06 ± 1.021 73.55 ± 1.343 NS 72.629 ± 0.15 NS 
Renal Cyst Volume (mL) 3.34 ± 0.357 3.11 ± 0.134 NS 2.574 ± 0.145 S 
Liver Weight (LW) g 1.36 ± 0.0698 1.296 ± 0.03 NS 1.302 ± 0.02 NS 
LW % BW 4.63 ± 0.23 4.93 ± 0.19 NS 4.86 ± 0.14 NS 
Heart Weight (HW) 0.30 ± 0.11 0.275 ± 0.014 NS 0.242 ± 0.009 S 
HW % BW 1.02 ± 0.06 1.04 ± 0.05 NS 0.91 ± 0.04 NS 
 
n=7 n=8 
 
n=8 
 Brain Perimeter (cm) 4.045 ± 0.433 4.167 ± 0.383 NS 4.131 ± 0.352 NS 
Brain Area (cm2) 0.406 ± 0.108 0.419 ± 0.049 NS 0.414 ± 0.056 NS 
 
n=3 n=2 
 
n=2 
 Renal Cyst Volume (CT 
Scans) 72.257 ± 5.932 66.518 ± 4.980 NS 64.562 ± 3.289 NS 50 
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Figure 2: Human Cyst Fluid Addition to Apical and Basolateral side of the mpkCCDcl4 
renal cell line  
 
The apical and basolateral cyst fluid stimulation of ion transport (SCC) of a monolayer of 
mpkCCDcl4 cells grown on transwells.  At time = -10 minutes, cyst fluid was added to the 
apical side to obtain a final concentration of 10%.  A time= 0 minutes, cyst fluid was 
added to the basolateral side to obtain a final concentration of 10%.  In both cases an 
equal amount of serum-free media was added to the opposing side to balance the addition 
of cyst fluid.   
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Figure 3: Stimulatory response to the addition of 50M LPA to the basolateral side of the 
mpkCCDcl4 renal cell line 
 
Confluent monolayers cultures were kept in normal conditions assembled into the Ussing 
chambers, until the vehicle (DMSO) was added at t= -30 minutes to the apical side.  At 
time=0 minutes, 50 M LPA was added to the basolateral side.  1x10-5 M Amiloride was 
added apically after 30 minutes to inhibit sodium flux. 
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Figure 4: Inhibition of cyst fluid (CF-12) stimulated chloride secretion in mpkCCDcl4 
cells with known inhibitors of CFTR and CaCCs 
 
 A. Confluent monolayers of mpkCCDcl4 renal cells grown on permeable supports, they 
were excised and mounted into Ussing chambers.  The cells were allowed appropriate 
amount of time to develop a stable basal short circuit current (SCC).  The graph shows 
the measurement of SCC, net ion transport.  50 M GlyH-101 and 20 M tannic acid 
were added at time= -30 minutes to the apical side as indicated.  At time = 0 minutes, CF-
12 was added to the basolateral side to obtain a final concentration of 10%, subsequently 
an equal amount of serum free media was added to the basolateral side to equal out the 
pressure.  1x10-5 M Amiloride was added apically 30 minutes after the LPA addition to 
inhibit sodium flux.  B. The second graph depicts the ion transport events in an expanded 
time frame. 
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Figure 5: Inhibition of LPA stimulation with CFTR and CaCC inhibitors 
 
A. Confluent monolayers of mpkCCDcl4 renal cells grown on permeable supports, they 
were excised and mounted into Ussing chambers.  The cells were allowed appropriate 
amount of time to develop a stable basal short circuit current (SCC).  The graph shows 
the measurement of SCC, net ion transport.  50 M GlyH-101 and 20 M tannic acid 
were added at time= -30 minutes to the apical side as indicated.  At time=0 minutes, 50 
M LPA was added basolaterally.  1x10-5 M Amiloride was added to the apical side 30 
minutes after the LPA addition to inhibit sodium flux.  B. The second graph depicts the 
ion transport events in an expanded time frame. 
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Figure 6: Testing the Stimulatory Capacity of Human Cyst Fluid from Multiple Patients 
 
A.  Confluent monolayers of mpkCCDcl4 renal cells grown on permeable supports, they 
were excised and mounted into Ussing chambers.  The cells were allowed appropriate 
amount of time to develop a stable basal short circuit current (SCC).  The graph shows 
the measurement of SCC, net ion transport.  At time= 0 different cyst fluids from 
different patients were added to the basolateral bathing media.  For control, at time=0, 50 
M LPA was added to the basolateral bathing media.  1x10-5 M Amiloride was added 
apically after 30 minutes to inhibit sodium flux.  Each plot represents a single 
experiment.  B. The second graph depicts the ion transport events in an expanded time 
frame. 
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Figure 7: Comparison of LPA	and	ADH	stimulation	of	ion	transport	in	the	mpkCCDcl4	
renal	cell	line  
 
Confluent monolayers of mpkCCDcl4 renal cells grown on permeable supports, they were 
excised and mounted into Ussing chambers.  The cells were allowed appropriate amount 
of time to develop a stable basal short circuit current (SCC).  The graph shows the 
measurement of SCC, net ion transport.  At time= 0, 50 M LPA or 100 mU/mL ADH 
was added to the basolateral bathing media.  1x10-5 M Amiloride was added apically after 
30 minutes to inhibit sodium flux. 
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Figure 8: Inhibition of the fetal bovine serum (FBS) stimulation with CFTR and CaCC 
inhibitors 
 
A. Confluent monolayers of mpkCCDcl4 renal cells grown on permeable supports, they 
were excised and mounted into Ussing chambers.  The cells were allowed appropriate 
amount of time to develop a stable basal short circuit current (SCC).  The graph shows 
the measurement of SCC, net ion transport.  50 M GlyH-101 and 20 M tannic acid 
were added at time= -30 minutes to the apical side as indicated.  At time=0 minutes, 10% 
FBS was added basolaterally, subsequently an equal amount of serum free media was 
added to the basolateral side to equal out the pressure.  1x10-5 M Amiloride was added to 
the apical side 30 minutes after the LPA addition to inhibit sodium flux.  B. The second 
graph depicts the ion transport events in an expanded time frame. 
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Figure 9: Comparison of the basolateral stimulatory response of ether LPA and ester LPA 
	
Confluent monolayers of mpkCCDcl4 renal cells grown on permeable supports, they were 
excised and mounted into Ussing chambers.  The cells were allowed appropriate amount 
of time to develop a stable basal short circuit current (SCC).  The graph shows the 
measurement of SCC, net ion transport.  50 M ester or ether LPA was added 
basolaterally at time= 0 minutes as indicated by the arrow. 1x10-5 M Amiloride was 
added to the apical 30 minutes after LPA was added to inhibit sodium flux.  The 
experiment was also conducted at 50 nM LPA with a minor ion transport response (data 
not shown).   
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Figure 10: Inhibition of LPA stimulation with LPA 1/3 Receptor Antagonists (Ki6425 
and VPC51299) 
 
A. Confluent monolayers of mpkCCDcl4 renal cells grown on permeable supports, they 
were excised and mounted into Ussing chambers.  The cells were allowed appropriate 
amount of time to develop a stable basal short circuit current (SCC).  The graph shows 
the measurement of SCC, net ion transport.  At time= -30 minutes the LPA 1/3 receptor 
antagonists (Ki6425 and VPC51299) were added to the basolateral side as indicated.  At 
time= 0 minutes the 50 M LPA was added to the basolateral side.  1x10-5 M Amiloride 
was added after 30 minutes to inhibit sodium flux.  B. The second graph depicts the peaks 
in an expanded time frame. 
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Figure 11: Basolateral addition of Bapta-AM and Ionomyocin with LPA 
 
Confluent monolayers of mpkCCDcl4 renal cells grown on permeable supports, they were 
excised and mounted into Ussing chambers.  The cells were allowed appropriate amount 
of time to develop a stable basal short circuit current (SCC).  The graph shows the 
measurement of SCC, net ion transport.  At time= -30, either 0.1 mM Ionomyocin or 100 
mM Bapta-AM was added basolaterally.  At time= 0 minutes the 50 M LPA was added 
to the basolateral side.  1x10-5 M Amiloride was added after 30 minutes to inhibit sodium 
flux.   
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Figure 12: Basolateral addition of Bapta-AM and Ionomyocin with CF-12 
	
Confluent monolayers of mpkCCDcl4 renal cells grown on permeable supports, they were 
excised and mounted into Ussing chambers.  The cells were allowed appropriate amount 
of time to develop a stable basal short circuit current (SCC).  The graph shows the 
measurement of SCC, net ion transport.  At time= -30, either 0.1 mM Ionomyocin or 100 
mM Bapta-AM or a vehicle was added basolaterally.  At time= 0 minutes 10% CF-12 
was added basolaterally, subsequently an equal amount of serum free media was added to 
the basolateral side to equal out the pressure.  1x10-5 M Amiloride was added after 30 
minutes to inhibit sodium flux.   
 
	 	
Time (min)
-10 0 10 20 30 40
SC
C
 ( 
A/
cm
2 )
-2
0
2
4
6
8
10
12
14
16
Control
10microM Bapta-AM
10microM Iono w/NO CF-12
10microM Ionomyocin
 Bapta-AM/Iono
CF-12
	 63
			
Figure 13: Inhibition of the fetal bovine serum (FBS) stimulation with T16AinhA-01 
	
Confluent monolayers of mpkCCDcl4 renal cells grown on permeable supports, they were 
excised and mounted into Ussing chambers.  The cells were allowed appropriate amount 
of time to develop a stable basal short circuit current (SCC).  The graph shows the 
measurement of SCC, net ion transport.  At time= -30 minutes, the chloride channel 
inhibitors were added (5 M T16Ainh-A01, 20 M T16Ainh-A01, 25 M GlyH-101, 25 
M GlyH-101/ 5 M T16Ainh-AO1) to the apical side.  At time= 0 minutes, 10% FBS 
was added basolaterally, subsequently an equal amount of serum free media was added to 
the basolateral side to equal out the pressure.  1x10-5 M Amiloride was added after 30 
minutes to inhibit sodium flux.   
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Figure 14: Inhibition of the cyst fluid (CF-12) stimulation with digalliac acid (DA) 
 
Confluent monolayers of mpkCCDcl4 renal cells grown on permeable supports, they were 
excised and mounted into Ussing chambers.  The cells were allowed appropriate amount 
of time to develop a stable basal short circuit current (SCC).  The graph shows the 
measurement of SCC, net ion transport.  At time= -30 minutes, the chloride channel 
inhibitors were added (50 M GlyH-101, 30 M digalliac acid, 60 M digalliac acid, 50 
M GlyH-101/ 30 M digalliac acid, 50 M GlyH-101/ 60 M digalliac acid) to the 
apical side.  At time= 0 minutes, 10% CF-12 was added basolaterally, subsequently an 
equal amount of serum free media was added to the basolateral side to equal out the 
pressure.  1x10-5 M Amiloride was added after 30 minutes to inhibit sodium flux.   
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Figure 15: Immunohistochemical confocal staining of the mpkCCDcl4 renal cell line for 
TMEM16A 
 
Confluent monolayers of mpkCCDcl4 renal cells were grown on permeable supports at 
which they cells were fixed using 4% paraformaldehyde.  The cells were immunolabeled 
with antibodies specific for TMEM16A and AN01 (green) and actin (red).  The center 
image is the 2-dimensional view, while the side images are a composite of the confocal 
images, to represent the 3-dimensional staining on the cells. 
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Figure 17: Concentration of cAMP (pmol/cm2) determined after stimulation of various 
agents with the mpkCCDcl4 renal cell line   
 
Samples were collected from after stimulation with various reagents (LPA, ADH, and 
Forskolin) for the time frames of 20 seconds, 1 minute, and 5 minutes.  A cAMP assay 
was completed on duplicates of the samples and their optical density was determined at 
405 nm.  Using a log scale, the concentration of cAMP (pmol/mL) was determined by 
using the standard curve and graphing the mean optical density (OD) to determine the 
corresponding concentration.  Significance was determined by comparing the samples to 
the control using a students t-test, p value less than 0.05 were considered signifcant. 
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Figure 18: Fluid secretion after 5 minutes of LPA stimulation on the basolateral side of 
the mpkCCDcl4 renal cell line 
	
Confluent monolayers of mpkCCDcl4 renal cells were grown on permeable supports.  The 
feeding media was changed 24 hours prior to experiment.  The cells were stimulated with 
0.114 mM LPA on the basolateral side, after 5 minutes of gently swirling the secreted 
fluid, along with the original 1.5 mL of media was collected and weighed.  Significance 
was completed by comparing the control LPA stimulated mass, in which 1 L of fluid is 
1 g of mass.  A students t-test was used in which a p value of less than 0.05 is 
considered significant. 
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Figure 19: Fluid secretion after 24 hours of LPA stimulation on the basolateral side of the 
mpkCCDcl4 renal cell line 
 
Confluent monolayers of mpkCCDcl4 renal cells were grown on permeable supports.  The 
cells were stimulated with 0.114 mM LPA on the basolateral side for 24 hours.  500 L 
of mineral oil was added to reduce the loss of fluid due to evaporation. secreted fluid 
along with the original 1.5 mL of media was collected, and was centrifuged to removed 
the oil, then weighed.  Significance was completed by comparing the control LPA 
stimulated mass, in which 1 L of fluid is 1 g of mass.  A students t-test was used in 
which a p value of less than 0.05 is considered significant. 
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Figure 20: Rosiglitazone treated PCK rats body weight comparison for control, high, 
intermediate, and low dose treatment 
 
Animals were fed rosiglitazone at the concentrations listed starting at the time of weaning 
(4 weeks) for 24 weeks.  Body weight data are plotted as means + SEM.  Statistics were 
completed using Prostat, using one-tailed Anova, using a student t-test a p value less than 
0.05 was considered significant.  Further statistics were completed using the Anova one-
way testing and Anova F-test, in which the null hypothesis of the control vs. rosiglitazone 
treated were equal, if rejected, the data was significant. 
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Figure 21: Rosiglitazone treated PCK rats total kidney weight (A) and kidney weight as a 
percent of Body weight (KW%BW) (B) comparison for control, high, intermediate, and 
low dose treatment 
 
Animals were fed rosiglitazone at the concentrations listed starting at the time of weaning 
(4 weeks) for 24 weeks.  Total Kidney Weight (A) and KW%BW (B) data are plotted as 
means + SEM.  Statistics were completed using Prostat, using one-tailed Anova, using a 
student t-test a p value less than 0.05 was considered significant.  Further statistics were 
completed using the Anova one-way testing and Anova F-test, in which the null 
hypothesis of the control vs. rosiglitazone treated were equal, if rejected, the data was 
significant. 
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Figure 22: Rosiglitazone treated PCK rats renal cyst volume percentage (Vv) (A) and 
renal cyst volume (B) comparison for control, high, intermediate, and low dose treatment 
 
Animals were fed rosiglitazone at the concentrations listed starting at the time of weaning 
(4 weeks) for 24 weeks.  Renal cyst volume percentage (Vv) (A) and renal cyst volume 
(B) data are plotted as means + SEM.  Statistics were completed using Prostat, using one-
tailed Anova, using a student t-test a p value less than 0.05 was considered significant.  
Further statistics were completed using the Anova one-way testing and Anova F-test, in 
which the null hypothesis of the control vs. rosiglitazone treated were equal, if rejected, 
the data was significant. 
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Figure 24: Rosiglitazone treated PCK rats total liver weight (A) and liver weight as a 
percent of Body weight (LW%BW) (B) comparison for control, high, intermediate, and 
low dose treatment 
 
Animals were fed rosiglitazone at the concentrations listed starting at the time of weaning 
(4 weeks) for 24 weeks. Total liver weight (A) and LW%BW (B) data are plotted as 
means + SEM.  Statistics were completed using Prostat, using one-tailed Anova, using a 
student t-test a p value less than 0.05 was considered significant.  Further statistics were 
completed using the Anova one-way testing and Anova F-test, in which the null 
hypothesis of the control vs. rosiglitazone treated were equal, if rejected, the data was 
significant. 
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Figure 25: Rosiglitazone treated PCK rats liver percent fibrocystic comparison for 
control, high, intermediate, and low dose treatment 
 
Animals were fed rosiglitazone at the concentrations listed starting at the time of weaning 
(4 weeks) for 24 weeks.  Liver percent fibrocystic data are plotted as means + SEM.  
Statistics were completed using Prostat, using one-tailed Anova, using a student t-test a p 
value less than 0.05 was considered significant.  Further statistics were completed using 
the Anova one-way testing and Anova F-test, in which the null hypothesis of the control 
vs. rosiglitazone treated were equal, if rejected, the data was significant. 
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Figure 26: Rosiglitazone treated PCK rats heart weight comparison for control, high, 
intermediate, and low dose treatment 
 
Animals were fed rosiglitazone at the concentrations listed starting at the time of weaning 
(4 weeks) for 24 weeks.  Heart weight data are plotted as means + SEM.  Statistics were 
completed using Prostat, using one-tailed Anova, using a student t-test a p value less than 
0.05 was considered significant.  Further statistics were completed using the Anova one-
way testing and Anova F-test, in which the null hypothesis of the control vs. rosiglitazone 
treated were equal, if rejected, the data was significant. 
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Figure 27: 10 Day Pioglitazone treated W-WPK rats glucose (A) and hematocrit (B) 
comparison for control, high, and low dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 10.  Glucose (A) and hematocrit (B) data are plotted as 
means + SEM.  Statistics were completed using Prostat, using one-tailed Anova, using a 
student t-test a p value less than 0.05 was considered significant.  Further statistics were 
completed using the Anova one-way testing and Anova F-test, in which the null 
hypothesis of the control vs. rosiglitazone treated were equal, if rejected, the data was 
significant. 
 
  
Control High, 2.0 Low, 0.2
m
g/
dL
0
100
200
300
400
500
n=7 n=2 n=4
Control High, 2.0 Low, 0.2
Pe
rc
en
ta
ge
 (%
)
0
5
10
15
20
25
30
n=7 n=6 n=5
A.
B.
	 78
 
 
Figure 28: 10 Day Pioglitazone treated W-WPK rats body weight comparison for control, 
high, and low dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 10.  Body weight data are plotted as means + SEM.  
Statistics were completed using Prostat, using one-tailed Anova, using a student t-test a p 
value less than 0.05 was considered significant.  Further statistics were completed using 
the Anova one-way testing and Anova F-test, in which the null hypothesis of the control 
vs. rosiglitazone treated were equal, if rejected, the data was significant. 
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Figure 29: 10 Day Pioglitazone treated W-WPK rats total kidney weight (A) and kidney 
weight as a percent of body weight (KW%BW) (B) comparison for control, high, and low 
dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 10.  Total kidney weight (A) and KW%BW (B) data are 
plotted as means + SEM.  Statistics were completed using Prostat, using one-tailed 
Anova, using a student t-test a p value less than 0.05 was considered significant.  Further 
statistics were completed using the Anova one-way testing and Anova F-test, in which 
the null hypothesis of the control vs. rosiglitazone treated were equal, if rejected, the data 
was significant. 
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Figure 30: 10 Day Pioglitazone treated W-WPK rats renal cyst volume percentage (Vv) 
(A) and renal cyst volme (B) comparison for control, high, and low dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 10.  Renal cyst volume percentage (Vv) (A) and renal cyst 
volume (B) data are plotted as means + SEM.  Statistics were completed using Prostat, 
using one-tailed Anova, using a student t-test a p value less than 0.05 was considered 
significant.  Further statistics were completed using the Anova one-way testing and 
Anova F-test, in which the null hypothesis of the control vs. rosiglitazone treated were 
equal, if rejected, the data was significant. 
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Figure 31: 10 Day Pioglitazone treated W-WPK rats total liver weight (A) and liver 
weight as a percent of body weight (LW%BW) (B) comparison for control, high, and low 
dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 10.  Total liver weight (A) and LW%BW (B) data are 
plotted as means + SEM.  Statistics were completed using Prostat, using one-tailed 
Anova, using a student t-test a p value less than 0.05 was considered significant.  Further 
statistics were completed using the Anova one-way testing and Anova F-test, in which 
the null hypothesis of the control vs. rosiglitazone treated were equal, if rejected, the data 
was significant. 
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Figure 32: 10 Day Pioglitazone treated W-WPK rats total heart weight (A) and heart 
weight as a percent of body weight (HW%BW) (B) comparison for control, high, and low 
dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 10.  Total heart weight (A) and HW%BW (B) data are 
plotted as means + SEM.  Statistics were completed using Prostat, using one-tailed 
Anova, using a student t-test a p value less than 0.05 was considered significant.  Further 
statistics were completed using the Anova one-way testing and Anova F-test, in which 
the null hypothesis of the control vs. rosiglitazone treated were equal, if rejected, the data 
was significant. 
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Figure 33: 10 Day Pioglitazone treated W-WPK rats CT renal cyst volume percentage 
comparison for control, high, and low dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 10.  CT renal cyst volume percentage are plotted as means 
+ SEM.  Statistics were completed using Prostat, using one-tailed Anova, using a student 
t-test a p value less than 0.05 was considered significant.  Further statistics were 
completed using the Anova one-way testing and Anova F-test, in which the null 
hypothesis of the control vs. rosiglitazone treated were equal, if rejected, the data was 
significant. 
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Figure 34: 18 Day Pioglitazone treated W-WPK rats glucose (A) and hematocrit (B) 
comparison for control, high, and low dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 18.  Glucose (A) and hematocrit (B) data are plotted as 
means + SEM.  Statistics were completed using Prostat, using one-tailed Anova, using a 
student t-test a p value less than 0.05 was considered significant.  Further statistics were 
completed using the Anova one-way testing and Anova F-test, in which the null 
hypothesis of the control vs. rosiglitazone treated were equal, if rejected, the data was 
significant. 
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Figure 35: 18 Day Pioglitazone treated W-WPK rats body weight comparison for control, 
high, and low dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 18.  Body weight data are plotted as means + SEM.  
Statistics were completed using Prostat, using one-tailed Anova, using a student t-test a p 
value less than 0.05 was considered significant.  Further statistics were completed using 
the Anova one-way testing and Anova F-test, in which the null hypothesis of the control 
vs. rosiglitazone treated were equal, if rejected, the data was significant. 
 
  
Control High, 2.0 Low, 0.2
W
ei
gh
t (
g)
0
20
25
30
35
n=10 n=8 n=11
	 86
 
Figure 36: 18 Day Pioglitazone treated W-WPK rats total kidney weight (A) and kidney 
weight as a percent of body weight (KW%BW) (B) comparison for control, high, and low 
dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 18.  Total kidney weight (A) and KW%BW (B) data are 
plotted as means + SEM.  Statistics were completed using Prostat, using one-tailed 
Anova, using a student t-test a p value less than 0.05 was considered significant.  Further 
statistics were completed using the Anova one-way testing and Anova F-test, in which 
the null hypothesis of the control vs. rosiglitazone treated were equal, if rejected, the data 
was significant. 
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Figure 37: 18 Day Pioglitazone treated W-WPK rats renal cyst volume percentage (Vv) 
(A) and renal cyst volme (B) comparison for control, high, and low dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 18.  Renal cyst volume percentage (Vv) (A) and renal cyst 
volume (B) data are plotted as means + SEM.  Statistics were completed using Prostat, 
using one-tailed Anova, using a student t-test a p value less than 0.05 was considered 
significant.  Further statistics were completed using the Anova one-way testing and 
Anova F-test, in which the null hypothesis of the control vs. rosiglitazone treated were 
equal, if rejected, the data was significant. 
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Figure 38: 18 Day Pioglitazone treated W-WPK rats total liver weight (A) and liver 
weight as a percent of body weight (LW%BW) (B) comparison for control, high, and low 
dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 18.  Total liver weight (A) and LW%BW (B) data are 
plotted as means + SEM.  Statistics were completed using Prostat, using one-tailed 
Anova, using a student t-test a p value less than 0.05 was considered significant.  Further 
statistics were completed using the Anova one-way testing and Anova F-test, in which 
the null hypothesis of the control vs. rosiglitazone treated were equal, if rejected, the data 
was significant. 
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Figure 39: 18 Day Pioglitazone treated W-WPK rats total heart weight (A) and heart 
weight as a percent of body weight (HW%BW) (B) comparison for control, high, and low 
dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 18.  Total heart weight (A) and HW%BW (B) data are 
plotted as means + SEM.  Statistics were completed using Prostat, using one-tailed 
Anova, using a student t-test a p value less than 0.05 was considered significant.  Further 
statistics were completed using the Anova one-way testing and Anova F-test, in which 
the null hypothesis of the control vs. rosiglitazone treated were equal, if rejected, the data 
was significant. 
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Figure 40: 18 Day Pioglitazone treated W-WPK rats brain perimeter (A) and brain area 
(B) comparison for control, high, and low dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 18.  Brain perimeter (A) and brain area (B) data are 
plotted as means + SEM.  Statistics were completed using Prostat, using one-tailed 
Anova, using a student t-test a p value less than 0.05 was considered significant.  Further 
statistics were completed using the Anova one-way testing and Anova F-test, in which 
the null hypothesis of the control vs. rosiglitazone treated were equal, if rejected, the data 
was significant. 
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Figure 46: 18 Day Pioglitazone treated W-WPK rats CT renal cyst volume percentage 
comparison for control, high, and low dose treatment 
 
Animals were fed pioglitazone at the concentrations listed starting at day 5 of age and 
continued on treatment till day 10.  CT renal cyst volume percentage are plotted as means 
+ SEM.  Statistics were completed using Prostat, using one-tailed Anova, using a student 
t-test a p value less than 0.05 was considered significant.  Further statistics were 
completed using the Anova one-way testing and Anova F-test, in which the null 
hypothesis of the control vs. rosiglitazone treated were equal, if rejected, the data was 
significant. 
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